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Description
FIELD OF THE INVENTION
[0001] The present invention relates to 1-azaspiro[3.5] nonan-2- ona-5,7-carbolactone and 5,7- protected-I-azaspiro
[3.5] nonan-2-one derivatives, a method for their synthesis and their use in the synthesis of TTX and TTX analogues.
BACKGROUND OF THE INVENTION
[0002] Tetrodotoxin (TTX), Octahydro-12-(hydroxymethyl)- 2- imino- 5,9: 7,10a- dimethano-10aH-[1,3] dioxocino[6,5-d]
pyrimidine-4,7,10,11,12-pentol, is a potent neurotoxin which selectively binds to sodium channel proteins inhibiting its
function in the cell membrane. Tetrodotoxin was first isolated in 1909 from the ovaries of the puffer fish, and named after
the puffer fish family "Tetraodontidae’’. Despite being a small molecule, it has an extremely complex structure charac-
terised by a dioxaadamantane skeleton, a guanidine residue which is part of an hemiaminal, and an orthoacid bridge.
[0003] It should also be noted that TTX is usually present as a mixture of two possible tautomers: an orthoester and
a hydroxyllactone. The ratio of both tautomers depends on the media in which TTX is present. 
[0004] Due to its novel structure and high density of functional groups, only after extensive efforts, Hirata-Goto et al.
(Goto, T.; Kishi, Y.; Takahashi, S.; Hirata, Y. Tetrahedron 1965, 21, 2059-2088); Tsuda et al. (Tsuda, K.; Ikuma, S.;
Kawamura, M.; Tachikawa, K.; Sakai, K.; Tamura, C.; Amakasu, O. Chem. Pharm. Bull. 1964, 12, 1357-1374) and
Woodward et al. (Woodward, R. B. Pure Appl. Chem. 1964, 9, 49-74; Woodward, R. B.; Gougoutas, J. Z. J. Am. Chem.
Soc. 1964, 86, 5030) independently arrived at the same structure in 1964. Finally, in 1970 absolute stereochemistry
was determined unambiguously by X-ray crystallographic analysis of its derivative (Furusaki, A.; Tomie, Y.; Nitta, I. Bull.
Chem. Soc. Jpn. 1970, 43, 3325-3331).
[0005] Tetrodotoxin blocks diffusion of sodium through the sodium channel, preventing depolarization and propagation
of action potentials in nerve cells. The TTX-Na Channel binding site is extremely tight (Kd = 10-10 nM). Therefore it is
an essential tool in pharmacological studies related to sodium channel proteins.
[0006] Further, Tetrodotoxin, due to its analgesic properties, is a promising new drug candidate in the field of pain
management
[0007] Extraction and purification of natural TTX is complicated, and dependent on the availability of the right animal
source. Therefore there is an existing need of providing larger amounts of Tetrodotoxin and its analogues, and researchers
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seek new cost effective and efficient synthesis. Up to the date, only a handful of total synthesis has been reported (Kishi,
Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; Tetrahedron Lett. 1970, 59, 5127-5128; Kishi, Y.; Nakatsubo,
F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; Tanino, H.; Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9217-9219; Kishi,
Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; Tanino, H.; Sugiura, S. J. Am. Chem. Soc. 1972, 94,
9219-9220; Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; Tanino, H.; Sugiura, S. J. Am. Chem.
Soc. 1972, 94, 9220-9221), Isobe et al. in January 2003 (Isobe,M. et al, J.Am.Chem.Soc, 2003, 125, 8798-8805). Dubois
et al. in June 2003 (Du Bois, J.; Hinman, A. J. Am. Chem. Soc. 2003, 125, 11510-11511), and Isobe et al. have reported
an additional asymmetric total synthesis comprising 62 steps and an overall yield of approximately 1%, from a vinilic
methyl intermediate (Isobe, M.; Urabe, D.; Nishikawa, T. Angew. Chem. Int. Ed. 2004, 43, 4782-4785). Further improve-
ments by the same author have been published on 2006 (Isobe, M.; Urabe, D.; Nishikawa, T.; Urabe, D. Chem. Asian.
J. 2006, 1-2, 125-135).
[0008] For the purposes of the present invention "TTX analogues" are those described in US 5,846,975 (included
herein by reference). From column 3 line 40 to column 6 line 40 US 5,846,975 describes a general formula of known
TTX analogues, for example, anhydrotetrodotoxin, tetrodaminotoxin, methoxytetrodotoxin, ethoxytetrodotoxin, deox-
ytetrodotoxin and tetrodonic acid, 6 epi-tetrodotoxin, 11- deoxytetrodotoxin as well as the hemilactal type TTX derivatives
(e.g. 4- epi- TTX, 6- epi- TTX, 11-deoxy- TTX, 4-epi- 11-deoxy- TTX, TTX-8-O-hemisuccinate, chiriquitoxin, 11-nor-TTX-
6 (S)-ol, 11-nor-TTX- 6 (R)-ol, 11-nor-TTX- 6,6-diol, 11-oxo-TTX and TTX-11-carboxylic acid), the lactone type TTX de-
rivatives (e.g. 6-epi- TTX (lactone), 11-deoxy-TTX (lactone), 11-nor- TTX- 6 (S)-ol (lactone), 11-nor-TTX- 6 (R)-ol (lactone),
11-nor-TTX-6,6- diol (lactone), 5-deoxy- TTX, 5,11-dideoxy- TTX, 4-epi- 5,1 1-didroxy-TTX, 1-hydroxy-5,11-dide-
oxy-TTX, 5,6,11-trideoxy-TTX and 4-epi-5,6,11-trideoxy-TTX) and the 4,9-anhydro type TTX analogs (e.g. 4,9-anhydro-
TTX, 4,9-anhydro- 6-epi- TTX, 4,9-anhydro-11- deoxy-TTX, 4,9-anhydro-TTX- 8-O-hemisuccinate, 4,9-anhydro-TTX-
11-O-hemisuccinate). The typical analogues of TTX possess only 1/8 to 1/40 of the toxicity of TTX in mice, based upon
bioassay in mice. It has been observed that these derivatives produce joint action, and do not interact adversely.
[0009] Also, Isobe has reported the synthesis of different unnatural analogues of Tetrodotoxin following similar strat-
egies as those reported for Tetrodotoxin. Concretely, Isobe et al. has reported the synthesis of (-)- 5,11- Dideoxytetro-
dotoxin (Isobe, M.; Asai, M.; Ohyabu, N.; Yamamoto, N.; Nishikawa, T. Angew. Chem. Int. Ed. 1999, 38, 3081-3084),
(-)- 8,11-Dideoxytetrodotoxin (Isobe, M.; Asai, M.; Iwabuchi, T.; Yoshida, K.; Urabe, D.; Nishikawa, T. Org. Lett. 2002,
16, 2679-2682; Isobe, M.; Asai, M.; Iwabuchi, T.; Yoshida, K.; Urabe, D.; Nishikawa, T. Chem. Eur. J. 2004, 10, 452-462)
and 11-Deoxytetrodotoxin (Isobe, M.; Asai, Nishikawa, T. J. Am. Chem. Soc. 2002, 124, 7847-7852).
[0010] Finally. Sato et al. have recently reported an asymmetric total synthesis of Tetrodotoxin from myo-inositol in
approximately 0.14% overall yield after 40 steps (Sato, K.; Akai, S.; Sugita, N. ; Ohsawa, T. ; Kogure, T. ; Shoji, H. ;
Yoshimura, J. J. Org. Chem. 2005, 70, 7496-7504).
[0011] Also, further discussions regarding different synthetic approaches to Tetrodotoxin and its analogues may be
reviewed in Koert, U. T. Angew. Chem. Int. Ed. 2004, 43, 5572-55769.
[0012] In view of all of the above there is an existing need of providing an alternative cost effective and efficient
synthesis of Tetradotoxin and analogues thereof, which can be used for the industrial production of sufficient amounts
of these compounds. Further new analogues with useful biological and pharmacological properties will be readily available
by means of new synthetic strategies.
BRIEF DESCRIPTION OF THE FIGURES
[0013]
Figure 1 is a representation of the molecular structure obtained using X-rays diffraction of rac- (4R, 5R,6R,7S, 8S,
9S)- 1-benzyloxy-7-(benzoyloxymethyl)-6-(tert-butyldimethyl silyloxy)- 5-cyano-5,7,8,9-tetrahydroxy- 8,9-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)- 1-azaspiro[3.5] nonan-2-one (7). Hydrogen atoms have been omitted for the sake
of clarity.
Figure 2 is a representation of the molecular structure obtained using X- rays diffraction of rac- (4S, 5R, 6S, 7R, 8S,
9S)- 1-benzyloxy-7-(benzyloxylmetyl)- 6-(tert- butyldimethylsililoxi)- 5,8,9-trihydroxy- 8,9-O-(1,1,3,3-tetraisopropyldis-
iloxane- 1,3-diyl)-1- azaspiro[3.5] non- 2-ona- 5,7-carbolactone (10). Hydrogen atoms have been omitted for the sake
of clarity.
SUMMARY OF THE INVENTION
[0014] In their ongoing efforts the inventors have found that a new class of 1-azaspiro [3.5] nonan-2- ona- 5,7-carbolac-
tone and 5,7-protected-1-azaspiro [3.5] nonan- 2-one derivatives are promising intermediates for the synthesis of TTX
and analogues thereof. Thus, a first aspect of the invention is directed to a compound of formula (I) as defined below
(from now on, "compound of formula (I)" or "compound of the invention").
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[0015] A second aspect of the invention is a method for the synthesis of a compound of formula (I) from a compound
of formula (II), (III), (IV) or (V) as defined below.
[0016] A third aspect of the invention is directed to the use of a compound of formula (I) as intermediate in the synthesis
of TTX or analogues thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0017] For the purposes of the present invention the compounds of general formula (I), (Ia), (la’), (Ib) and (Ib’) have
been also nominated as "compounds of the invention". Compounds described herein ((I), (Ia), (Ia’), (Ib), (Ib’), (II), (III),
(IV), (V), (VI), (VII), (VIII)) have been numerated as described below when referred to:
- Compounds of formula (II), (III), (IV), (V), (VI), (VII) and (VIII): 
- Compounds of formula (Ia) and (Ia’):
- Compounds of formula (Ib) and (Ib’):
[0018] However, IUPAC prelation rules have been applied when naming individual compounds (see examples).
[0019] In the present application the following numbering will be used when reference is made to TTX or analogues
thereof (see figure 1, page 7497 in Sato, K.; Akai, S.;  Sugita. N.: Ohsawa, T.: Kogure. T.: Shoji, H.: Yoshimura, J. J.
Org. Chem. 2005. 70, 7496-7504): 
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Compounds of formula (I)
[0020] As mentioned above, a first aspect of the present invention is directed to a compound of formula (I)
wherein
R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-OPr, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl and NReRf, wherein Re and Rf are each independently selected from
H, OH, OPr, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino and halogen; and
R3 is selected from hydrogen, OH, OPr or =O; or
R1 and R3 together form a group selected from -CH2-O- Pr-O- and -CH2-O-PrC(R11R12)-O-, the oxygen terminus
being attached to the C6 carbon atom (as shown in the above figure, C6 is the carbon atom which supports R3);
wherein R11 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl,
substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy; and R12 is selected from the group consisting
of cyano, substituted or unsubstituted alkyl and aziridine;
R9 and R10 are each independently selected from hydrogen, OH, OPr or =O;
R5 is selected from the group consisting of hydrogen, -CN,-OH, OPr and a carbonyl derivative of formula -C(=O)
Rg, wherein Rg is a selected form the group consisting of hydrogen, substituted or unsubstituted alkoxy, substituted
or unsubstituted aryloxy and substituted or unsubstituted amine;
L is selected from the group consisting of
• -O- C(=X)-, wherein X is selected from NPrn, NH or O, and the carbon atom supporting X is attached to C5 (as
shown in the above figure, C5 is the carbon atom which supports R5);; and
• Z, wherein Z is selected from the group consisting of -O-C(R6R7)-O-, - O- Si (R6R7)-O- and -O- Si (R6R7)-O- Si
(R6R7)-O-, wherein each of R6 and R7 are independently selected from the group consisting of hydrogen,
substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted hetero-
cyclyl;
W is selected from the group consisting of-H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted alke-
nyl;
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Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or un-
substituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or
unsubstituted amino and halogen;
Pr is a hydroxyl protecting group; and
Pm is an amino protecting group;
or its tautomers, salts or solvates thereof.
[0021] The compounds of formula (I) are specially interesting intermediates for the synthesis of TTX and analogues
thereof because unwanted dehydration, elimination and epimerization reactions are avoided. Due to the dense func-
tionalitation of the compounds of the invention, these side reactions are frequent. The presence of acid hydrogen atoms
in β position with respect to heteroatoms or potential leaving groups may give raise to elimination reactions. Also,
epimerization and substitution processes facilitated by anchimeric assistance are a problem. Anchimeric assistance is
also known as neighbouring group participation or NGP and has been defined by IUPAC as the interaction of a reaction
centre with a lone pair of electrons in an atom or the electrons present in a sigma bond or pi bond. For example, if a
heteroatom with a lone pair of electrons is in alfa position with respect to a potential leaving group, said lone pair of
electrons may displace the leaving group, activating the carbon atom which supported said leaving group. However, the
carbon atom which supports the heteroatom also becomes activated, which is a source of unwanted substitution reactions,
lost of regioselectivity or epimerization processes. For example, if two vecinal axial hydroxyl groups in a cyclohexane
are in relative anti positions, dehydration may readily proceed. This is the situation for many intermediates of TTX,
specially with regard to positions C5, C6, C7 and/or C8. Fixing cyclation between the substituents of C5 and C7 prevents
such dehydrations.
[0022] The invention also provides salts of compounds of formula (I) with biologically and pharmacologically acceptable
inorganic and organic acids, non- limiting examples of which are sulphates; hydrohalide salts; phosphates; lower alkane
sulphonates; arylsulphonates; salts of C1 -C20 aliphatic mono-, di- or tribasic acids which may contain one or more
double bonds, an aryl nucleus or other functional groups such as hydroxy, amino, or keto; salts of aromatic acids in
which the aromatic nuclei may or may not be substituted with groups such as hydroxyl, lower alkoxyl, amino, mono- or
di- lower alkylamino sulphonamido. Also included within the scope of the invention are quaternary salts of the tertiary
nitrogen atom with lower alkyl halides or sulphates, and oxygenated derivatives of the tertiary nitrogen atom, such as
the N- oxides. In preparing dosage formulations, those skilled in the art will select the pharmaceutically acceptable salts.
[0023] The term "solvate" according to this invention is to be understood as meaning any form of the active compound
according to the invention which has another molecule (most likely a polar solvent) attached to it via non-covalent
bonding. Examples of solvates include hydrates and alcoholates, e.g. methanolate.
[0024] Tautomers of the compounds described herein are also included in the scope of the present application. For
example, tautomers of the compounds of formula (I), (Ia), (Ia’), (Ib), (Ib’), (II), (III), (IV), (V), (VI), (VII) or (VIII) may arise
from the rearrangement of the azaspiro [3.5] none to an azaoxaspiro [4.5] decenone:
[0025] This tautomerization may take place due to strong acid or basic condition as described in our co-pending
application EP06380204.5, as well as a consequence of heat (thermal rearangement). These tautomers are also suitable
intermediates for the synthesis of TTX and analogues thereof and are included within the scope of the invention.
[0026] Another example of tautomerism of the compounds of formula (I), (Ia), (Ia’), (Ib), (Ib’), (II), (III), (IV), (V), (VI),
(VII) or (VIII) are enolates of carbonyl compounds. The acid hydrogens which are alfa to a carbonyl functionality may
be readily displaced to form the corresponding enol-tautomer, which is usually far less stable than the corresponding
carbonyl-tautomer. However, the enol may become more stable or trapped. Thus, the enol tautomers are also included
in the scope of the invention. This is specially relevant in the case of alfa- hydroxyketones, wherein the two carbon atoms
may share the carbonyl/enol tautomeric character in variable degrees:
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[0027] These tautomers are also included within the scope of the invention.
[0028] According to an embodiment of the present invention the compound of formula (I) is a compound of formula (Ia)
wherein
R1, R3, R9, R10, Ra, Rb, W and X are as defined in formula (I): and
R5 is selected from the group consisting of hydrogen, -OH or OPr ; or its tautomers, salts or solvates thereof.
[0029] According to a further embodiment of the present invention the compound of formula (I) is a compound of
formula (Ib)
wherein
R1, R3, R9, R10, Ra, Rb, Z and W are as defined in formula (I); or its tautomers, salts or solvates thereof.
[0030] According to a preferred embodiment, R1 is -CH2-OPr, preferably selected from the group consisting of-CH2-OC
(=O) alkyl and -CH2-OC(=O) Aryl.
[0031] According to a preferred embodiment, R1 and R3 together are -CH2-O- Pr-O-, wherein Pr is a hydroxyl protecting
group.
[0032] According to a preferred embodiment, R9 and R10 together are -O-Pr-O-, wherein Pr is a hydroxyl protecting
group.
[0033] According to a preferred embodiment, a compound of formula (Ia) is a compound of formula (Ia’)
EP 1 956 024 A1
8
5
10
15
20
25
30
35
40
45
50
55
wherein R5, R11, Ra, X, Pr and W are defined as in formula (Ia); or its tautomers, salts or solvates thereof.
[0034] According to a preferred embodiment, R5 is hydrogen.
[0035] According to a preferred embodiment. R5 is -OH.
[0036] According to a preferred embodiment, X is O.
[0037] According to a preferred embodiment, a compound of formula (Ib) is a compound of formula (Ib-)
wherein Ra, R11,, Z, Pr and W are defined as in formula (I); or its tautomers, salts or solvates thereof.
[0038] According to a preferred embodiment, when R1 and R3 together are -CH2-O- Pr-O-.
[0039] According to a preferred embodiment R1 and R3 together are -CH2-O-C(R11R12)-O-.
[0040] According to a preferred embodiment R11 is substituted or unsubstituted aryl.
[0041] According to a preferred embodiment R12 is cyanide.
[0042] According to a preferred embodiment, W is aralkyl, preferably -CRcRd-aryl, wherein Rc and Rd are each
independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substi-
tuted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino and halogen.
[0043] According to a preferred embodiment, Rc and Rd are different.
[0044] According to a preferred embodiment, W is -CRcH- aryl, wherein Rc is not hydrogen, that is, wherein Rc is
selected from the group consisting of OH, OPr, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substi-
tuted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino and halogen.
[0045] According to a preferred embodiment, Rc and Rd are both hydrogen.
[0046] According to a preferred embodiment, Ra and Rb are different. According to a preferred embodiment, Ra and
Rb are both hydrogen.
Synthesis of the compounds of formula (I)
[0047] There are different synthetic approaches for the preparation of compounds of formula (I): 
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(i) cyclizating a cis-compound of formula (II);
(ii) reacting a compound of formula (III) with -CN and, optionally, if the cyano group and the hydroxyl group are not
in cis relative position, epimerizating the resulting compound of formula (II);
(iii) dihydroxylating a compound of formula (IV);
(iv) hydrogenating a compound of formula (V); or
(v) protecting the diol on the C5 and C7 positions of a trans-compound of formula (II). A trans-compound of formula
(II) is a compound of formula (II) wherein the cyanide C5 is cis with regard to R2.
[0048] The above mentioned procedures are explained in detail below. First, the methods for the synthesis of com-
pounds of formula (Ia) are explained (methods (i), (ii), (iii) and (iv)) and then method (v) for the synthesis of compounds
of formula (Ib).
Synthesis of the compounds of formula (Ia)
[0049] The immediate precursors of the compounds of formula (Ia) are those wherein a hydroxyl group in C7 and a
cyano group in C5 are in cis relative position. The inventors have found that in such compounds cyclization takes place
readily to yield the compounds of formula (Ia).
[0050] A first method (method (i)) for the synthesis of a compound of formula (I), comprises the cyclation between the
R2 group and the cyano group of a compound of formula (II)
wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in formula (I);
R5 is selected from the group consisting of hydrogen, -OH and OPr; and
R2 is -OH or -OPr, Pr being a hydroxyl protecting group; wherein the cyano group and R2 are in relative cis positions;
or its tautomers, salts or solvates thereof.
[0051] Cyclation takes place easily under acid or basic conditions to yield a compound of formula (Ia).
[0052] If R2 is -OPr deprotection liberates the hydroxyl group necessary for cyclation, which may proceed without
further purification of the intermediate in a one-pot reaction.
[0053] Methods for obtaining the compounds of formula (II) are described in the PCT patent application
PCT/EP2006/068236 (not published) in the name of the same applicant. Thus, for example, PCT/EP2006/068236 already
discloses that a compound of formula (II) may be obtained by the nucleophylic attack of a cyanide anion to the carbonyl
moiety of a compound of formula (III) 
wherein R1, R3, R9, R10, Ra, Rb and W are as defined in formula (I); and R2 is - OH or -OPr, Pr being a hydroxyl protecting
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group; or its tautomers, salts or solvates thereof.
[0054] The cyanide anion necessary for the reaction may be obtained from various sources known to the skilled
person. For example, such sources may be selected from the following reagent systems: Ph3P/ diethyl azodicarboxylate
(DEAD) / alcohol/acetone cianhydrin (Synth. Com. 1995, 25, 1545-1550;  Synth. Com. 1993, 23, 2481-2484).
[0055] Other sources of cyanide anion are based on reagent systems comprising NaCN. Conditions already described
in the art comprise a mixture of NaCN with one of the following reaction systems: DMSO or nBu4NCN/DMF/heat (J.
Med. Chem. 1991, 56, 3009-3016; J. Med. Chem. 1966, 31, 2933-2941), DMSO/ heat (J. Med. Chem. 2001, 44, 94-104;
Tetrahedron Asymmetry, 1996, 7, 1967-1972), Bu4NCN/ DMSO/ heat (Bioorg. Med. Chem. Lett. 1999, 9, 841-846), DMF/
heat (Tetrahedron Letters, 1998, 39, 3357-3358; J. Med. Chem. 1994, 37, 4195-4210), [(CH3)2N]3PO (J. Chem. Soc.
Chem. Com. 1982, 7, 404-406) or conditions wherein sodium bicarbonate is present, such as NaCN/
NaHCO3/H2O/Et2O/r.t., NaCN/NaHCO3/Et2O/r.t. or NaCN/ NaHCO3/THF/-H2O (J. Med. Chem. 1992, 35, 2721-2727;
Carbohydrate Resarch 1991, 216, 399-411; J. Med. Chem. 1998, 41, 4636-4647 ; Carbohydrate Resarch 1991, 216,
399-411). Also, NaCN in the presence of 1-Methyl-1H-pyrrole provides the desired cyanide anion.
[0056] In another embodiment, the reaction may proceed in the presence of KCN (J. Am. Chem. Soc. 1958, 80,
4677-4680). Conditions already described in the art comprise a mixture of KCN with one of the following reaction systems:
Et2O/H2O (Tetrahedron Letters, 2001, 42, 6259-6262), THF/r.t. (Carbohydrate Resarch 1994, 254, 133-140) or
CH2Cl2/H2O/r.t., with or without NaHCO3 (J. Chem. Soc. Perkin Trans 1. 1985, 1067-1072).
[0057] In another embodiment, the reaction may proceed in the presence of LiCN. Conditions already described in
the art comprise a mixture of LiCN with one of the following reaction systems: Me3SiCl/THF/r.t. (Synthesis, 1986, 12,
1054-1055), DMF/[ (CH3)2N]3PO (Bioorg. Med. Chem. Lett. 1996, 6, 1897-1900), diethyl cyanidophosphate/THF/r.t.
(Chem. Pharm. Bull. 1986, 34, 4620-4628; Tetrahedron Letters, 1989, 30, 3681-3684) or DMF (Bioorg. Med. Chem.
Lett. 2000, 10, 2417-2419).
[0058] Copper cyanide is also a useful source of cyanide anion (CuCN/HNaCO3/H2O/EtO2 ; Tetrahedron. 1988, 44,
4895-4904).
[0059] In another embodiment, the reaction may proceed in the presence of HCN. Conditions already described in
the art comprise a mixture of HCN with one of the following reaction systems: Pyridine/r.t. (J. Chem. Soc. Perkin Trans
1. 1994, 1067-1072), Et3N/CH2Cl2/ 0°C (Carbohydrate Resarch 1986, 155, 236-246) or in situ generation of HCN by
mixing Zn (CN)2 and AlCl3 (Tetrahedron Asymmetry. 1990. 1, 187-198).
[0060] Thus, according to one embodiment, the reagent which provides a cyanide anion has a formula MCN, wherein
M is lithium, potassium, sodium or copper.
[0061] Trialkylsylil cyanides are also wide spread sources of cyanide anions (J. Orig. Chem. 2003, 3094-3103; J. Am.
Chem. Soc. 1973, 5822-5823; J. Chem. Soc. Perkin Trans 1. 1988, 2305-2307). Conditions already described in the art
comprise a mixture of trialkylsilyl cyanide with one of the following reaction systems: TMSCN/ DABCO or TMSCN/
(DHQ)2AQN (J. Am. Chem. Soc. 2003, 125, 9900-9901), TMSCN/BF3/CH2Cl2/r.t. or TMSCN/BF3·Ei2O/CH2Cl2/r.t. (Tet-
rahedron Letters, 1990, 31, 71-74; Tetrahedron Letters, 1990, 31, 71-74; Tetrahedron Letters, 1990, 31, 71-74; Carbo-
hydrate Resarch 1994, 258, 77-86), TMSCN/ crown ether/KCN (cat) / toluene/-30°C (J. Am. Chem. Soc. 1985, 107,
4577-4579; Tetrahedron Letters, 1994, 35, 7901-7904), TMSCN/ amine/CH2Cl2/ 0°C (Chemistry Letters. 1991, 125,
537-540), TMSCN/I2/ 20-30°C (Tetrahedron 2000, 35, 6533-6540), TMSCN/ZnI2/ heat (Tetrahedron Asimmetry. 1994,
9, 805-816), TMSCN/CaO/Toluene/- 40°C (J. Chem. Soc. Chem. Com. 1991, 15, 1035-1036), TMSCN/Ph3P(cat)/CH2Cl2
(Tetrahedron Letters, 1986, 27, 2757-2760), TMSCN/Lewis acid (Tetrahedron Letters, 1983, 39, 967-974), TMSCN/
catalyst (Tetrahedron 2001, 57, 771-779); TMSCN/ZnI2(cat) (Tetrahedron 1994, 50, 2821-2830), TBDM-
SCN/ZnI2/CH2Cl2 (J. Org. Chem. 1993, 58, 159-164; Bull. Chem. Soc. Jpn. 2001, 74, 997-1008), (alkyl)3SiCN/LiCl (cat)
/no solvent (J. Org. Chem. 2005, 70, 6530-6532).
[0062] According to a further embodiment, reagents which provide a cyanide anion are a dialkylaluminium cyandes
of formula (alkyl)2-Al- CN or a trialkylsilyl cyanide of formula (alkyl)3Si-CN, which are commercially available.
[0063] According to a preferred embodiment, the compound of formula (III) reacts in the presence of TMSCN or
Et2AlCN.
[0064] If R2 in the compound of formula (III) is a deprotected hydroxyl group or is deprotected due to reaction conditions,
the attack of the cyanide anion to the carbonyl group in C5 forms a compound of formula (II) which may undergo further
cyclation in the same reaction media or during workup, to yield a compound of formula (Ia).
[0065] The attack of the cyanide anion to a compound of formula (III) may yield two stereoisomers of formula (II), one
wherein the cyanide C5 is cis with regard to R2 (cis- compound of formula (II)), as a result of an equatorial attack, and
one wherein it is trans (trans-compound of formula (II)), as a result of an axial attack. As mentioned before, cis- compounds
of formula (II) yield compounds of formula (Ia), while trans- compounds of formula (II) do not. The proportion cis:trans is
variable and it can be controlled by an appropriate selection of reagents and conditions.
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[0066] For example, the reaction of a compound of formula (III) with Et2AlCN or NC- C(=O)-CH3 usually provides a
trans-compound of formula (II), as a result of an equatorial attack, while the reaction in the presence of TMSCN provides
a cis- compound of formula (II), as a result of an axial attack.
[0067] Regardless of the stereochemistry of the reaction, it is also possible to transform any trans-compound of formula
(II) into a cis-compound of formula (II) by a process of epimerization. For example, the reaction between a trans-compound
of formula (II) and di-tert-butylsilyl bis(trifluomethane)sulfonate in the presence of triethylamine yields the desired cis-
compound of formula (II) : 
[0068] As mentioned above, this cis- compound of formula (II) is readily transformed into a compound of formula (I),
either by further treatment or in the same reaction media:
[0069] It is also possible to epimirize a trans-compound of formula (II) into a cis-compound of formula (II) under
conditions such as those described on page 7499 of Sato, et al, J. Org. Chem., 2005, 70, 7496-7504 (see discussion
regarding the transformation of the compound 26a into the compound 26)
[0070] Thus, a second method (method (ii)) for the synthesis of a compound of formula (1), comprises the following
steps: 
a) reacting a compound of formula (III) as defined above in the presence of a reagent which provides cyanide anion
(-CN); and, if necessary,
b) epimerizing the C5 carbon atom of the compound of formula (II)obtained.
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[0071] Formation of compounds of formula (III) has been already disclosed in the PCT patent application
PCT/EP2005/005149 in the name of the applicant. For example, the compound of formula (III) may be obtained by
oxidation of a compound of formula (VI)
wherein R1, R2, R3, R9, R10, Ra, Rb and W are as defined in formula (III); or its tautomers, salts or solvates thereof.
[0072] According to a preferred embodiment, the compound of formula (VI) is a compound of formula (VII) 
wherein R2, R9, R10, R11, Ra, Rb and W are as defined in formula (I); or its tautomers, salts or solvates thereof. Oxidation
of said compound of formula (VII) provides a compound of formula (III), which may be transformed into a compound of
formula (II) by the methods described above.
[0073] The compounds of formula (VII) can be prepared by reaction of a compound of formula (VIII) 
wherein R2, R9, R10, R11, Ra, Rb and W are as defined in formula (I); or its tautomers, salts or solvates thereof; in the
presence of a reagent which provides a cyanide anion.
[0074] Therefore, according to a preferred embodiment, the method of the invention comprises
a) reacting a compound of formula (VIII), as defined above, in the presence of a reagent which provides a cyanide
anion, to obtain a compound of formula (VII) as defined above;
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b) oxidizing said compound of formula (VII) to obtain a compound of formula (III); and
c) reacting the compound of formula (III) obtained in step b) in the presence of a reagent which provides cyanide
anion (-CN); and, if necessary, epimerizing the C5 carbon atom of the compound of formula (II) obtained.
[0075] In the above reaction, reagents which provide a cyanide anion are preferably the same as in steps a) and c).
Also, dialkylaluminium cyandes of formula (alkyl)2-Al-CN are preferred. 
The use of the same reagent in both reactions makes the overall process more simple, which is especially important on
the industrial scale.
[0076] The compounds of formula (VIII) can be prepared by methods already disclosed in PCT/EP2005/005149 and
PCT/EP2006/068236.
[0077] As mentioned above, cyclation between the cyanide group of C5 and the hydroxyl group of C7 takes place
readily. Since such cyclation may take place in the reaction media once both groups are cis, without the need of separating
the intermediate compound of formula (II), the inventors have further devised methods (iii) and (iv) for the synthesis of
the compounds of formula (Ia).
[0078] Method (iii) comprises dihydroxylating the double bond between C7 and C10 of a compound of formula (IV)
wherein
R3, R9, R10, Ra, Rb and W are as defined in formula (I); and
R5 is selected from the group consisting of hydrogen, -OH and OPr; or its tautomers, salts or solvates thereof.
[0079] That is, the hydroxyl group on C7 is introduced in a compound wherein the cyano group on C5 is already present
[0080] Dihydroxylation may be performed by methods described in PCT/EP2005/005149 (see examples 15 and 22
therein).
[0081] Method (iv), comprises hydrogenation of a compound of formula (V):
wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in formula (I), and
R2 is -OH or -OPr;
or its tautomers, salts or solvates thereof, to yield a compound of formula (Ia).
[0082] That is, according to method (iv), both, the hydroxyl group on C7 and the cyano group on C5 are present in
the starting material (compound of formula (V)), but not in the required cis position. Effecting a reaction which provides
the desired cis position provides the desired compounds of formula (II) with the necessary stereochemistry for cyclation.
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[0083] Preparation of the compounds of formula (V) has been already described in PCT/EP2006/068236. For example,
they may be prepared from compounds of formula (III) 
[0084] The reaction conditions for the above mentioned reactions are known to the skilled person. Triflation is a
standard reaction which may be performed, for example, following conditions described in Tetrahedron Lett. 1984, 25,
595-598. Introduction of a cyano group may be performed by nucleophilic substitution following, for example, the con-
ditions described in Can. J. Chem. 1993, 71, 1867-1872.
Synthesis of compounds of formula (Ib)
[0085] Contrary to the compounds of formula (Ia), the immediate precursors of the compounds of formula (Ib) are the
trans-compounds of formula (II), wherein the hydroxyl groups in C5 and C7 have the appropriate cis configuration:
[0086] Once the C5 and C7 hydroxyl groups are in cis position, it is possible to simultaneously protect both with a diol
protecting group by methods known in the art. Methods for protecting 1,3- diols can be found in the literature (see Greene
and Wuts "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999). Non limitative examples
of reagents for diol protection which may provide the compounds of formula (Ib) from the trans-compounds of formula
(II) are listed (typical non- limitative are indicated in the parenthesis): 
Cyclic acetals and ketals of formula (alkylO)2C(R6R7) (e.g. (MeO)2CH2/ LiBr/TsOH/CH2CL2/r.t.), acetonides of for-
mula (alkylO)C(R6)=CH2 (e.g. CH3C(OMe) =CH2/TsOH/DMF), benzylidene acetals of formula ArCHO or aralkyl-
CHO (e.g. PhCHO/ ZnCl2, PhCHO/DMSO/H2SO4, PhCHO/TsOH/ reflux/- H2O, PhCHBr2/Pyr, PhCH
(OMe)2/HBF4/Et2O/DMF, PhCH(OMe)2/SnCl2/DME/ heat, Ph (OCH2CH2CH=CH2)2 /CSA/NBS, KHMDS/ PhCHO),
methoxybenzyllidene acetals (p-MeOC6H4CHO/acid, p-MeOPhCHO/ TMSOTf/CH2Cl2/-78° C, p-
MeOC6H4CH2OMe/DDQ/CH2Cl2, - p-MeOC6H4CH(OMe)2/ acid (CSA)/DMF, p- MeOC6H4CH2OMe/ ZnCl2), di-t-bu-
tylsilylene group of formula (t-Bu)2Si(OR)2 ((t- Bu)2SiCl2/CH3CN/TEA/HOBt, (t-Bu)2Si(OTf)2/ 2,6-lutidine/CHCl3, (t-
Bu)2SiCl2/ AgNO3/Pyr/DMF, (t-Bu)2Si (OTf)2/DMF/Pyr), 1,3-(1,1,3,3-Tetraisopropyldisiloxanylidene) derivates of for-
mula TIPDS(OR)2 (TIPDSCl2/DMF/ Imidazole, TIPDSCl2/Pyr, TIPDSCl2/ AgOTf/sym-collidine/DMF) or 1,1,3,3- Tet-
ra-t- butoxydisiloxanylidene derivates of formula TBDS(OR)2 (1,3 Dichloro- 1,1,3,3-tetra-t-butoxydisiloxane/Pyr) or
compounds of formula
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wherein X is FSO3 or BF4 (K2CO3 or Pry/CH2Cl2)
[0087] Although each of the procedures described herein use known reagents, their application in the present invention
provides new compounds and unexpected results in terms of reactivity and selectivity.
[0088] In view of the above, a second aspect of the invention is a method for the synthesis of a compound of formula
(I) which comprises one of the following methods:
(i) cyclation between the R2 group and the cyano group of a compound of formula (II)
wherein
R1, R3, R5, R9, R10, Ra, Rb and W are as defined in formula (I); and
R2 is -OH or -OPr, Pr being a hydroxyl protecting group; wherein the cyano group and R2 are in relative cis
positions;
or its tautomers, salts or solvates thereof;
(ii) reacting a compound of formula (III)
wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in formula (1); and
R2 is -OH or -OPr, Pr being a hydroxyl protecting group;
or its tautomers, salts or solvates thereof;
in the presence of a reagent which provides cyanide anion (-CN); and, if necessary, epimerizing the C5 carbon atom
of the compound of formula (II) obtained;
(iii) dihydroxylating the double bond between C7 and C10 of a compound of formula (IV) 
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wherein
R3, R5, R9, R10, Ra, Rb and W are as defined in formula (I);
or its tautomers, salts or solvates thereof;
(iv) hydrogenate a compound of formula (V)
wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in formula (I); and
R2 is -OH or -OPr;
or its tautomers, salts or solvates thereof; or
(v) diol protection of hydroxyl groups on C5 and C7 of a compound of formula (II)
wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in formula (I); and
R2 and R5 are both independently a -OH group in cis relative positions;
or its tautomers, salts or solvates thereof.
[0089] The use of protecting groups of a certain size, or that are linked simultaneously to two different positions can
therefore control the stereochemistry of the product.
[0090] Thus the different intermediate compounds of the invention and the starting materials can be prepared using
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a basic set of simple reactions that allow the protection, functionalization of the different positions in a very stereospecific
manner. These procedures will be explained below. Throughout the description and claims the configurations given are
only relative configurations.
[0091] Enantiomeric compounds of those described in the present application may be prepared using starting materials
or reagents (for example, Sharpless dihydroxilation or epoxidation of a double bond) which have the opposite optical
rotation. Additionally, conventional techniques for the separation of diastereoisomers and enantiomers are common
general knowledge to the skilled person.
[0092] As mentioned above, the starting materials of the present invention may be obtained by processes described
in PCT/EP2005/005149, PCT/EP2006/068236 and/or PCT/EP2005/005146. Key intermediates described in
PCT/EP2005/005146 are benzodienones with the following formula
wherein the substitution on position Z may create a stereogenic center. In PCT/EP2005/005146 a preferred embodiment
is one wherein Z is -CRaRb-, wherein Ra and Rb are different thus creating a chiral center. Thus, according to a preferred
embodiment Ra and Rb in the compounds of formula (I) of the present invention are different, thus creating a chiral center.
[0093] Also, PCT/EP2005/005146 discloses as a preferred embodiment compounds wherein the substituent W of the
above benzodienones is an aralkyl group, more preferably wherein W is -CRaRb-Q, wherein Ra and Rb in the linker
have essentially the same meaning as in the present application and substituent Q has pi (pi) interactions with the
benzodienone moiety. Thus, another source of chirality arises when Ra and Rb in said linker are different, preferably
wherein W is -CHRa- Q (e.g. (-)-(S)-1-(1-Phenylethoxy)- 1-azaspiro[3.5]nona-5,8-diene-2,7-dione, which is described as
compound 5d in PCT/EP2005/005146). As disclosed in PCT/EP2005/005146 such configuration provides a stereogenic
center which allows selectivity or specificity of any further reaction, distinguishing the two double bonds of the of the
above mentioned benzodienones, which are intermediates in the synthesis of the compounds of the invention. This will
advantageously open the way to diastero- and/or enantioselective synthesis. Therefore, according to a preferred em-
bodiment, W in the compounds of formula (I) of the present invention is -CRcRd- aryl, more preferably Rc and Rd are
different, and more preferrably W is -CHRc-aryl.
[0094] The above mentioned compound may be a prochiral molecule, for example, if R1, R2, R3 and R4 are hydrogen.
Thus, treatment with chiral reagents will provide the enantiomerically pure intermediate which may drive an enantiose-
lective and diastereoselective synthesis. For example, a Sharpless dihydroxilation or epoxidation will provide the corre-
sponding enantiomerically pure dihydroxyl or epoxide.
[0095] PCT/EP2005/005149 also describes the possibility of obtaining chiral compounds following analogous proc-
esses.
[0096] Therefore, using the chiral materials described in PCT/EP2005/005149, PCT/EP2006/068236 and/or
PCT/EP2005/005146, it is possible to obtain the specific stereoisomers and enantiomers of the compounds described
in the present invention.
Definitions
[0097] In the present document the following terms have the meaning indicated:
"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms, containing
no saturation, having 1-12, preferably one to eight, more preferably, one to six carbon atoms, and which is attached
to the rest of the molecule by a single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t- butyl, n- pentyl, etc.
"Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms,
containing at least one unsaturation, having 2-12, preferably two to eight, preferably two to six carbon atoms, and
which is attached to the rest of the molecule by a single bond.
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"Alkynyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms,
containing at least one carbon-carbon triple bond, conjugated of not, having two to twelve, preferably two to eight
six, preferably two to six carbon atoms, and which is attached to the rest of the molecule by a single bond, such as
-CCH, -CH2CCH, -CCCH3, -CH2CCCH3, and which is attached to the rest of the moiecuie by a single bond.
"Aryl" or "Ar" refers to an aromatic hydrocarbon radical such as phenyl, naphthyl or anthracyl.
"Aralkyl" refers to an aryl group linked to an alkyl group such as benzyl and phenethyl.
’’Cycloalkyl" refers to a saturated carbocyclic ring having from 3 to 8 carbon atoms.
"Alkoxy" refers to a radical of the formula -Oalkyl, e. g., methoxy, ethoxy, propoxy, etc. "Aryloxy’’ refers to a radical
of formula -Oaryl.
"Heterocyclyl" refers to a stable 3- to 15- membered ring which consists of carbon atoms and from one to five
heteroatoms selected from the group consisting of nitrogen, oxygen, and sulphur, preferably a 4- to 8-membered
ring with one or more heteroatoms, more preferably a 5-or 6-membered ring with one or more heteroatoms. For the
purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic ring system, which may include
fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidised;
the nitrogen atom may be optionally quatemized; and the heterocyclyl radical may be partially or fully saturated or
aromatic. Examples of such heterocycles include, but are not limited to, azepines, benzimidazole, benzothiazole,
furan, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran.
"Amino" refers to a radical of the formula-NH2, -NHR", -NR"R"’, wherein R" adn R’" independently represent a group
selected from the group consisting of substituted of unsubstituted alkyl, substituted of unsubstituted alkenyl, sub-
stituted of unsubstituted alkynyl, substituted of unsubstituted aryl and substituted of unsubstituted aralkyl.
"Hydroxyl protecting group" refers to a group that blocks the OH function for further reactions and can be removed
under controlled conditions. The hydroxyl protecting groups are well known in the art, representative protecting
groups are: 
- silyl ethers of formula -Si (R’)3, such as trimethylsilyl ether, triethylsilyl ether, tert- butyldimethylsilyl ether, tert-
butyldiphenylsilyl ether, tri-isopropylsilyl ether, diethylisopropylsilyl ether, thexyldimethylsilyl ether, triphenylsilyl
ether, di- tert-butylmethylsilyl ether;
- alkyl and arylalkyl ethers such as methyl ether, tert-butyl ether, benzyl ether, p- methoxybenzyl ether , 3,4-
dimethoxybenzyl ether, trityl ether; allyl ether;
- alkoxymethyl and aryloxy ethers of formula -CH2-O- R’, such as methoxymethyl ether, 2-methoxyethoxymethyl
ether, benzyloxymethyl ether, p-methoxybenzyloxymethyl ether, 2-(trimethylsilyl)ethoxymethyl ether; tetrahy-
dropyranyl and related ethers; methylthiomethyl ether;
- Esters of formula -C(=O) R’, such as acetate ester, benzoate ester; pivalate ester; methoxyacetate ester; chlo-
roacetate ester; levulinate ester;
- Carbonates of formula -C(=O)-O- R’, such as benzyl carbonate, p-nitrobenzyl carbonate, tert-butyl carbonate,
2,2,2- trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, allyl carbonate; and
- sulphates such as SO3.py.
[0098] In all the above formula R’ represents a group selected from the group consisting of substituted of unsubstituted
alkyl, substituted of unsubstituted alkenyl, substituted of unsubstituted alkynyl, substituted of unsubstituted aryl and
substituted of unsubstituted aralkyl. Additional examples of hydroxyl protecting groups can be found in reference books
such as Greene and Wuts "Protective Groups in Organic Synthesis’’, John Wiley & Sons, Inc., New York, 1999.
[0099] "Amino protecting group" refers to a group that blocks the NH2 function for further reactions and can be removed
under controlled conditions. The amino protecting groups are well known in the art, representative protecting groups
are carbamates, e.g. carbamates of formula -C(=O) OR’; amides, e.g. amides of formula -C(=O) R’, such as substituted
or unsubstituted or substituted acetates; or silyl moieties of formula -Si (R’)3; wherein R’ represents a group selected
from the group consisting of substituted of unsubstituted alkyl, substituted of unsubstituted alkenyl, substituted of un-
substituted alkynyl, substituted of unsubstituted aryl and substituted of unsubstituted aralkyl.. Also different alkyl moeties
may serve as amino protecting groups. Said alkyl groups may optionally be substituted by one or more substituents
such as halo, hydroxy, alkoxy, alkyloxymethyl ethers, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro,
mercapto and alkylthio. Additional examples of amino protecting groups can be found in reference books such as Greene
and Wuts "Protective Groups in Organic Synthesis’’, John Wiley & Sons, Inc., New York, 1999.
[0100] References herein to substituted groups in the compounds of the present invention refer to the specified moiety
that may be substituted at one or more available positions by one or more suitable groups, e. g., halogen such as fluoro,
chloro, bromo and iodo ; cyano; hydroxyl ; nitro ; azido ; alkanoyl such as a C1-6 alkanoyl group such as acyl and the
like ; carboxamido ; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon
atoms and more preferably 1-3 carbon atoms ; alkenyl and alkynyl groups including groups having one or more unsatu-
rated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms ; alkoxy groups having one or more
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oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms ; aryloxy such as phenoxy ; alkylthio
groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms or from 1
to about 6 carbon atoms ; alkylsulfinyl groups including those moieties having one or more sulfinyl linkages and from 1
to about 12 carbon atoms or from 1 to about 6 carbon atoms ; alkylsulfonyl groups including those moieties having one
or more sulfonyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ; aminoalkyl groups
such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ;
carbocylic aryl having 6 or more carbons, particularly phenyl or naphthyl and aralkyl such as benzyl. Unless otherwise
indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each
substitution is independent of the other.
[0101] Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ
only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures
except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-
enriched carbon or 15N- enriched nitrogen are within the scope of this invention.
[0102] The invention will be further illustrated by means of examples, which should not be interpreted as limiting the
scope of the claims.
EXAMPLES
General Methods and Materials
[0103] All reactions described below were carried out under argon atmosphere unless otherwise noted. The solvents
used were distilled and dried under argon atmosphere before use. All starting materials were purchased commercially
(Aldrich, Fluka and Merck) and used without further purification. Flash Chromatography was executed on columns loaded
with 230-400 mesh silica gel Merck. TLC was carried out on silica gel Merck (Kieselgel 60F-254).
[0104] 1H and 13C NMR spectra were obtain on Varian Inova- 300 and Varian Inova-400 spectrometers using CDCl3
as solvent and (CH3)4Si as an internal reference unless otherwise noted. 1H and 13C NMR spectral data are reported
in parts per million (δ) relative to residual signal of the solvent (CHCl3, 7.26 ppm and 77.0 ppm for 1H and 13C NMR,
respectively). 1H and 13C NMR designations are: s (singlete); br. s (broad singlete); d (doublete); br. d (broad doublete);
t (triplete); q (quartete); m (multiplete). Infrared (IR) spectra were record on a Perkin-Elmer FT- IR spectrometer. Low-
resolution mass (LRMS) spectra were obtained: (1) on a Hewlett Packard 5973 MSD spectrometer with a direct inlet
system (EI) at 70 eV, (2) on a Hewlett Packard LCMS 1100 MSD spectrometer with a chemistry technical by electrospray
(API-ES) positive or negative at 4000 V at 330°C and using a mixture [1:1] H2O/ MeOH with 1% AcOH as movil phase.
Example 1:
Preparation of rac-(4S, 6S, 7R, 8S, 9S)- 1-Bencyloxy- 7-benzoyloxymethyl- 6-tert- butyldimethylsyliloxy-7,8,9-trihy-
droxy- 8,9-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-diyl)-1-azaspiro[3.5] nonane-2,5-dione (1)
[0105]
[0106] PCC (15 mg, 0,072 mmol, 1.5 eq.) was added to a solution of rac-(4R, 5S, 6S, 7S, 8R, 9R)- 1-benzyloxy- 7-ben-
zoyloxymethyl-8-tert-butyldimethylsilyloxy-5,6,7,9-tetrahydroxy- 5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-aza-
spiro[3.5] nonan-2- one (2) (39 mg, 0.048 mmol, 1.0 eq.) in CH2Cl2 (0,6 ml) and was stirred for 20 hours at room temper-
ature. After that time, a little amount of Celite was added and the solvent was eliminated under reduced pressure. The
product was purified by column chromatography (hexane/AcOEt, 10:1) and rac-(4S, 6S, 7R, 8S, 9S)-1-benzyloxy- 7-ben-
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zoyloxymethyl-6-tert-butyldimethylsilyloxy- 7,8,9-trihydroxy-8,9-O-(1,1,3,3- tetraisopropyldisiloxane- 1,3-diyl)- 1-azaspiro
[3.5] nonane-2,5-dione (1) (36 mg. 92% yield) was obtained as a white solid. Also, the starting product 2 (2 mg, 5%) and
an isomer of 70 (1mg, 3% yield) was recovered as a white solid.
P.f.: 163-164 °C.
Rf = 0.53 (TLC, hexano/ AcOEt, 3: 1).
1H- NMR (200MHz, CDCl3): δ 8.03 (2H, dm, J = 6.9 Hz, Bz), 7.64 (1H, tm, J = 7.3 Hz, Bz), 7.49 (2H, ddm, J = 7.3, 6.9
Hz, Bz), 7.44-7.27 (5H, m, Ph), 5.17 (2H, s, OCH2Ph), 4.85 (1H, d, J = 4.2 Hz, H- 9), 4.79 (1 H, part A syst. AB, J = 11.7
Hz, H- 10), 4,57 (1H, dd, J = 4.2, 1.3 Hz, H- 8), 4.56 (1H, part B syst. AB, J = 11.7 Hz, H- 10’), 4.12 (1H, d, J = 1.3 Hz, H-
6), 3.47 (1H, part A syst. AB, J = 13.5 Hz, H- 3), 2.95 (1 H, s, OH), 2.69 (1H, part B syst. AB, J = 13.5 Hz, H- 3’), 1.18-0.94
(28H, m, TIPDS), 0.88 (9H, s, C(CH3)3), 0.08 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). 
13C-NMR (75MHz, CDCl3): δ 203.1 (C-5), 167.3, 164.7, 135.6, 133.8, 129.7, 128.9, 128.6, 128.2, 78.6, 77.6 (C-6), 75.0
(C- 7), 74.6 (C-8), 72.5 (C- 4), 68.5 (C- 9), 66.6, 39.9 (C- 3), 25.6, 18.0, 17.7, 17.4, 17.35, 17.3, 17.2, 17.1, 17.0, 16.9,
13.9, 13.15, 13.1, 13.05, -4.7, -5.6.
IR (film): ν 3398, 2947, 2889, 2862, 1763, 1725, 1602, 1588, 1461, 1411, 1385, 1322, 1266, 1150, 1119, 1067, 998,
950, 889, 872, 840, 778 cm-1. 
LRMS (API- ES+): m/z 1650 (2M+Na)+, 836 (M+Na)+, 814 (M+H)+. 
E.A. (C41H63NO10Si3): Found: C, 60.59; H, 7.86; N, 1.95. Calculated: C, 60.48; H, 7.80; N, 1.72.
Example 2:
Preparation of rac-(4R, 5S, 6S, 7S, 8S, 9S)- 1-Benzyloxi- 7-benzoyloxymethyl- 8,9-epoxi- 5,6,7-trihydroxy-
5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-azaspiro [3.5]nonan- 2-one (3)
[0107]
[0108] tert-butyl hydroperoxide (86 Pl, 80% weight solution in (t-BuO)2, 0.689 mmol, 10.0 eq.) and molecular sieves
4Å were added at room temperature to a solution of rac- (4R, 5S, 6S, 7R)- 1-benzyloxi-7-benzoyloxymethyl-5,6,7-trihy-
droxy-5,6-O- (1,1,3,3,tetraisopropyldisiloxane-1,3- diyl)-1- azaspiro[3.5]non-8-en-2 one (4) (46 mg., 0.069 mmol, 1.0 eq.)
in CH2Cl2 (0.6 ml). After 10 minutes, VO(acac)2 (5mg, 0.021 mmol, 0,3 eq.) was added. The resultant mixture was stirred
at room temperature over 4 days. After that time, de mixture was diluted with CH2Cl2 (3 ml) and was filtered under
reduced pressure through Celite to eliminate the sieves. The solution was washed with an aqueous solution of NaHCO3
10% (2 ml), dried with anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure. The product
was purified by column chromatography (hexane/ AcOEt, 4: 1) and rac- (4R, 5S, 6S, 7S, 8S, 9S)-1-Benzyloxi- 7-benzoy-
loxymethyl- 8,9- epoxi- 5,6,7-trihydroxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-azaspiro[3.5] nonan-2-one (3)
(41 mg, 87% yield) was obtained as a white solid.
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[0109] Pyridine (2 Pl, 0.024 mmol, 2.0 eq.), a catalytic amount of 4-dimethylaminopyridine (0.01 eq.) and benzoyl
chloride (2 Pl, 0.014 mmol, 1.4 eq.) were sequentially added at 0°C, to a solution of rac-(4R, 5S, 6S, 7S, 8S, 9S)- 1-
benzyloxi-8,9-epoxi-5,6,7-trihydroxy-7- hydroxymethyl-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5]
nonan-2-one (5) (87 mg, 0.012 mmol, 1.0 eq.) in CH2Cl2 (0.15 ml). After 18 hours at room temperature, more pyridine
(2.0 eq.), DMAP (0.01 eq.) and benzoyl chloride (1.4 eq,) at 0°C were added, and the resulting mixture was stirred at
room temperature over 18 hours. After that time, the medium was neutralized by addition of saturated NaHCO3 and the
mixture was extracted with Et2O (3 x 2ml). The organic phase was washed with HCl 10% (2 ml) and NaCl saturated (2
ml), dried with anhydrous MgSO4, filtered and the solvent eliminated under reduced pressure. The product was purified
by column chromatography (hexane/ Ac=Et, 6:1) obtaining rac- (4R, 5S, 6S, 7S, 8S, 9S)- 1-Benzyloxi-7- benzoyloxyme-
thyl-8,9- epoxi- 5,6,7-trihydroxy- 5,6-O-(1,1,3,3-tetralsopropyldisiloxane-1,3-diyl)- 1-azaspiro [3.5] nonan- 2-one (3) 85 mg,
62% yield) as a white solid.
Rf= 0.36 (TLC, hexane/AcOEt, 3:1); 0.51 (TLC, hexane/ AcOEt, 2: 1). 
1H- NMR (200MHz, CDCl3): δ 8.07 (2H, dm, J= 7.0 Hz, Bz), 7.60 (1 H, tm, J = 7.3 Hz, Bz), 7.53-7.41 (4H, m, Bz y Ph),
7.41-7.31 (3H, m, Ph), 5.12 (1H, part A syst. AB, J = 11.0 Hz, OCH2Ph), 5.03 (1 H, part B syst. AB, J = 11.0 Hz, OCH2Ph),
4.58 (1H, part A syst. AB, J = 12.0 Hz, H-10), 4.53 (1H, s broad, H-5), 4.52 (1H, part B syst. AB, J = 12.0 Hz, H-10’),
4.24 (1H, s broad, H- 6), 3.52 (2H, s broad, H- 8 y H- 9), 3.16 (1H, part A syst. AB, J = 13.9 Hz, H-3), 2.81 (1H, s, OH),
2.48 (1H, part B syst. AB, J = 13.9 Hz, H-3’), 1.13-0.98 (28H, m, TIPDS).
1H- NMR (300MHz, C6D6): δ 8.16 (2H, dm, J = 8.3 Hz, Bz), 7.50 (1H, d, J = 7.6 Hz, Bz), 7.20-7.01 (7H, m, Bz y Ph), 5.10
(1H, part A syst. AB, J= 11.5 Hz, OCH2Ph), 5.06 (1H, part B syst. AB, J = 11.5 Hz, OCH2Ph), 4.76 (1 H, t, J = 1.9 Hz,
H-5 o H-6), 4.52 (1H, part A syst. AB, J = 11.7 Hz, H- 10), 4.45 (1H, part B syst. AB, J = 11.7 Hz, H- 10’), 4.28 (1H, m,
H-6 o H-5), 3.17 (1H, d, J= 13.7 Hz, H- 3), 3.02 (1H, m, H- 8 o H- 9), 2.96 (1H, dd, J = 3.7, 1.9 Hz, H-9 o H-8), 2.73 (1H,
m, OH), 2.18 (1 H, dd, J = 13.7, 1.9 Hz, H- 3’), 1.35-0.80 (28H, m, TIPDS).
1H- RMN (500MHz, CO(CD3)2): δ 8.12 (2H, m, Bz), 7.66 (1H, m, Bz), 7.57-7.46 (4H, m, Bz y Ph), 7.42-7.32 (3H, m, Ph),
5.12 (1H, part A syst. AB, J = 10.9 Hz, OCH2Ph), 5.06 (1H, part B syst. AB, J = 10.9 Hz, OCH2Ph), 4.98 (1H, s, OH),
4.88 (1H, d, J = 2.4 Hz, H-5), 4.59 (1H, part A syst. AB, J = 11.5 Hz, H- 10), 4.54 (1H, part B syst. AB, J = 11.5 Hz, H-
10’), 4.37 (1H, dd, J= 2.4, 1.3 Hz, H-6), 3.71 (1H, d, J = 3.7 Hz, H-9), 3.64 (1H, dd, J = 3.7, 1.3 Hz, H-8), 3.08 (1H, part
A syst. A B, J = 13.5 Hz, H- 3), 2.68 (1 H. part B syst. AB, J= 13.5 Hz, H- 3’), 1.23-0.92 (28H, m, TIPDS).
13C-RMN (75MHz, CDCl3): δ 166.4, 163.9, 135.2, 133.4, 129.6, 129.5, 128.9, 128.7. 128.5, 128.4, 78.8, 76.6 (C- 6), 71.4
(C- 7), 66.8 (C-10), 66.2 (C-5), 65.5 (C- 4), 60.3 (C- 9), 55.0 (C-8), 38.3 (C- 3), 17.6, 17.5, 17.2, 17.1, 17.0, 16.9, 14.3,
14.2, 13.5, 13.2.
13C-RMN (125MHz, CO(CD3)2): δ 166.9, 164.4, 136.9, 134.2, 131.2, 130.5, 129.8, 129.5, 129.4, 129.3, 79.2, 78.5 (C-
6), 72.3 (C-7), 68.7 (C-10), 67.8 (C-5), 66.6 (C-4), 59.8 (C-9), 56.2 (C-8), 38.8 (C-3), 18.2, 18.1, 17.7, 17.6, 17.55, 17.5,
15.4, 15.2, 14.4, 14.0.
IR (film): ν 3430, 2947, 2900, 2868, 1767, 1725, 1599, 1589, 1465, 1451, 1394, 1370, 1273, 1148, 1104, 1075, 1007,
941, 886, 823, 756, 711 cm-1. 
LRMS (API- ES+): m/z 1389 (2M+Na)+, 706 (M+Na)+, 684 (M+H)+. 
A.E. (C35H49NO9Si2): Found: C, 61.54; H, 7.37; N, 2.21. Calculated: C, 61.46; H, 7.22; N, 2.05.
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Example 3:
Preparation of rac-(4S, 5R, 6R, 7R, 8S, 9S)- 1-Bencyloxy- 7-benzoyloxymethyl-6-tert-butyldimethylsyliloxy-5-cy-
ano-8,9-dihydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diil)-5,7-bis (methoxycarbonoyloxy)- 1-azaspiro
[3.5]nonan- 2-one (6)
[0110]
[0111] To a solution of rac-(4S, 6S, 7R, 8S, 9S)- 1- bencyloxy-7-benzoyloxymethyl-6-tert-butyldimethylsyliloxy-7,8,9-tri-
hydroxy-8,9-O-(1,1,3,3-tetraisopropyldisyloxane-1,3-diil)-1-azaspiro [3.5] nonane-2,5-dione (1) (85 mg, 0,104 mmol, 1.0
eq.) and methyl cyanoformiate (100 Pl, 1.248 mmol, 12.0 eq.) in THF (1 ml) DABCO was added at room temperature
(3 mg, 0.026 mmol, 0.25 eq.). The resulting mixture was stirred at room temperature for 15 hours, after which solvent
was removed under reduced pressure. The residue was grinded with AcOEt, filtered through Celite and the solvent
removed under reduced pressure. The product was purified by silica gel column chromatography (hexane/AcOEt, 8: 1)
and rac- (4S, 5R, 6R, 7R, 8S, 9S)-1-Bencyloxy-7-benzoyloxymethyl- 6-tert-butyldimethylsyliloxy- 5-cyano-8,9-dihydroxy-
8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diil)- 5,7-bis(methoxycarbonoyloxy)- 1-azaspiro[3.5] nonan-2-one (6) (29 mg,
yield. 29%) was obtained as a white solid. An isomer was also isolated (5 mg, rto. 5%, Rf= 0.49 (TLC, hexane/ AcOEt, 3:1)). 
Rf = 0.41 (TLC, hexane/ AcOEt, 3: 1).
1H- NMR (300MHz, CDCl3): δ 7.98 (2H, , J = 6.9 Hz, Bz), 7.61 (1H,, J= 7.4 Hz, Bz), 7.53-7.41 (4H, m, Bz y Ph), 7.41-7.28
(3H, m, Ph), 5.56 (1H, d, J = 1.3 Hz, H-6), 5.14 (1H, dd, J = 4.0, 1.3 Hz, H- 8), 5.08 (1H, part A syst. AB, J = 12.0 Hz,
H-10), 5.05 (1H, pare A syst. AB, J = 10.1 Hz, OCH2Ph), 5.00 (1H, part B syst. AB, J = 10.1 Hz, OCH2Ph), 4.88 (1H,
d, J = 4.0 Hz, H-9), 4.83 (1H, part B syst. AB, J= 12.0 Hz, H- 10’), 3.90 (3H, s, OCH3), 3.62 (3H, s, OCH3), 3.45 (1H,
part A syst. AB, J = 14.8 Hz, H-3), 3.05 (1 H, part B syst. AB, J = 14.8 Hz, H-3’), 1.16-0.88 (28H, m, TIPDS), 0.95 (9H,
s, C(CH3)3), 0.40 (3H, s, SiCH3), 0.23 (3H, s, SiCH3). 
13C-NMR (75MHz, CDCl3): δ 167.0, 165.4, 152.9, 152.7, 135.3, 133.5, 129.4, 129.2, 128.9, 128.6, 128.3, 128.2, 115.1
(CN), 83.6 (C-7), 81.9 (C- 5), 78.7, 71.0 (C-8), 68.7 (C-6), 66.5 (C- 4), 65.2 (C-9), 61.9 (C-10), 55.8, 55.1, 38.8 (C-3),
26.4, 18.6, 17.6, 17.4, 17.3, 17.1, 17.0, 16.9, 16.8, 16.7, 13.5, 13.3, 13.1, 13.0, -3.3, -4.0.
IR (KBr): ν 3436, 2946, 2889, 2862, 2338, 1794, 1776, 1751, 1729, 1633, 1465, 1440, 1394, 1378, 1293, 1263, 1158,
1121, 1089, 1044, 995, 977, 922, 840, 785, 712 cm-1. LRMS (API- ES+): m/z 1936 (2M+Na)+, 1915 (2M+H)+, 1029
(M+73)+, 957 (M+H)+.
Examples for General Formula II and further epimerization (Compounds 7, 8, 11 and 14)
Example 4
Preparation of rac-(4R, 5R, 6R, 7S, 8S, 9S)- 1-benzyloxy- 7-(benzoyloxymethyl)- 6-(tert-butyldimethylsilyloxy)- 5-cy-
ano-5,7,8,9-tetrahydroxy -8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)- 1-azaspiro[3.5] nonan- 2-one (7) and 
rac- (4R, 5R, 6R, 7S, 8S, 9S)- 1-benzyloxy- 6-(tert- butyldimethylsilyloxy)-5-cyano- 5,7,8,9-tetrahydroxy-
8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 7-methylhydroxy- 1-azaspiro(3.5) nonan-2-one (8)
[0112]
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[0113] To a stirred solution of rac-(4S, 6S, 7R,8S, 9S)- 1-bencyloxy- 7-benzoyloxymethyl- 6-tert-butyldimethylsilyloxy-
7,8,9-trihydroxy- 8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)- 1-azaespiro[3.5] nonan- 2,5-dione (9) (92 mg, 0.113
mmol) in toluene (1 ml) at 0° C was added a solution of diethylaluminiumcyanide in toluene (1.0 M, 0.23 ml, 0.227 mmol).
The resulting mixture was stirred at room temperature until the reaction was complete (24 h, TLC monitoring, hexane/
AcOEt, 3: 1). The reaction was quenched at room temperature with a mixture 10% aqueous potassium- sodium tartrate
solution- AcOEt (1: 1, 4ml). The layers were separated and aqueous phase was extracted with AcOEt (3 x 4 ml). The
combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure to give rac- (4R,
5R, 6R,  7S,  8S,  9S)-  1-  benzyloxy- 7-(benzoyloxymethyl)-  6-(tert-  butyldimethylsilyloxy)- 5- cyano- 5,7,8,9- tetrahydroxy-
8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)-1-azaspiro[3.5] nonan- 2-one (7) (79 mg, 83%) as a white solid and rac-
(4R, 5R, 6R, 7S, 8S, 9S)-1-benzyloxy-6-(tert-butyldimethylsilyloxy)-5-cyano-5,7,8,9-tetrahydroxy-8,9-O-(1,1,3,3-tetraiso-
propyldisiloxane-1,3-diyl)- 7- methylhydroxy- 1-azaspiro [3.5] nonan-2-one (8) (10 mg, 10%) as a white solid.
Rf = 0.38 (TLC, hexane/ AcOEt 3:1) ; yield, 83% ; white solid ; m.p. : 160-162° C; 1H- NMR (300 MHz CDCl3): δ 8.05 (2H,
d, J = 8.3Hz, Bz), 7.66 (1H, m, Bz), 7.51 (2H, m, Bz), 7.44-7.26 (5H, m, Ph), 5.33 (1H, br. s, OH), 5.16 (1H, part A syst.
AB, J = 10.8 Hz, OCH2Ph), 5.11 (1H, part B syst. AB, J = 10.8 Hz, OCH2Ph), 4.91 (1H, d, J = 4.1 Hz, H- 9), 4.75 (1H,
br. s, OH), 4.71 (1H; part A syst. AB, J = 12.2Hz, H- 10), 4.67 (1H, part B syst. AB, J = 12.2 Hz, H- 10’), 4.52 (1H, dd, J
= 4.0, 1.5 Hz, H-8), 4.27 (1H, d , J = 1.5 Hz, H-6), 3.31 (1H, part A syst. AB, J = 14.7 Hz, H-3), 2.87 (1H, part B syst.
AB, J = 14.7 Hz, H-3’), 1.08-1.01, (28H, m, TIPDS), 0.96 (9H, s, C (CH3)3), 0.34 (3H, s, SiCH3), 0.28 (3H, s, SiCH3); 13C-
NMR (75 MHz, CDCl3):168.7, 167.2, 135.7, 134.3, 129.9, 128.82, 128.80, 128.4, 128.3, 118.1, 79.3, 78.5, 77.3, 75.4,
74.0, 67.9, 67.8, 64.9, 38.6, 26.5, 18.8, 17.8, 17.4, 17.31, 17.26, 17.15, 17.05, 16.8, 13.8, 13.07, 13.05, 13.04, 1.0, -
3.8, -4.2; LMRS(API- ES+): m/z 841 (M+H)+, 842 (M+2H)+, 843 (M+3H)+, 863 (M+Na)+, 1705 (2M+Na+H)+; IR (film): ν
3333.3, 2947.0, 2866.0, 2348.9, 1759.3, 1726.6, 1462.5, 1453.2, 1263.6, 1154.9, 1113.0, 1067.9, 999.6, 838.0, 779.0
cm-1.
X-ray Diffaction of rac-(4R, 5R, 6R, 7S, 8S, 9S)- 1-benzyloxy- 7-(benzoyloxymethyl)- 6-(tert-butyldimethylsilyloxy)-
5-cyano- 5,7,8,9-tetrahydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)- 1-azaspiro [3.5]nonan- 2-one (7)
[0114] A solution of rac-(4R, 5R, 6R,7S, 8S, 9S)- 1- benzyloxy- 7-(benzoyloxymethyl)-6-(tert-butyldimethylsilyloxy)- 5-cy-
ano-5,7,8,9-tetrahydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro [3.5] nonan-2-one (7) in AcOEt (24
mM, 0.5 ml) was crystallize by hexane diffusion.
[0115] Crystal structure determination was carried out using a Bruker-Nonius diffractometer equipped with a APPEX
2 4K CCD area detector, a FR591 rotating anode with MoKα radiation, Montel mirrors as monochromator and a Kryoflex
low temperature device (T = 100 K). Fullsphere data collection omega and phi scans. Programs used: Data collection
Apex2 V. 1.0-22 (Bruker-Nonius 2004), data reduction Saint + Version 6.22 (Bruker-Nonius 2001) and absorption cor-
rection SADABS V. 2.10 (2003). Crystal structure solution was achieved using direct methods as implemented in SHELX-
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TL Version 6.10 (Sheldrick, Universtität Göttingen (Germany), 2000) and visualized using XP program. Missing atoms
were subsequently located from difference Fourier synthesis and added to the atom list. Least-squares refinement on
F2 using all measured intensities was carried out using the program SHELXTL Version 6.10 (Sheldrick, Universtität
Göttingen (Germany), 2000). All non hydrogen atoms were refined including anisotropic displacement parameters.
Crystallographic data and experimental details for structural analyses are summarized in Table 1, whereas positional
parameters and atomic coordinates are given in Table 2 and Table 3. Figure 1 is a representation of the molecular
structure obtained using X-rays diffraction.
Table 1. Crystal data and structure
Empirical formula C42H64N2O10Si3
Formula weight 841.22
Temperature 100 (2) K
Wavelength (Å) 0.71073
Crystal system, space group Monoclinic, P21/n
Unit cell dimensions a = 11.9912 (10) Å a= 90°
b =14.7024 (13) Å b= 94.365(2)°
c = 25.768 (2)) Å g = 90°
Volume 4529.7 (7) Å3
Z 4
Calculated density 1.142 Mg/m3
P (mm-1) Absortion coefficient 0.149 mm-1
F(000) 1808
Crystal size 0.40 x 0.30 x 0.20 mm3
θ range for data collection 2.75 to 39.60°
Index ranges -21≤h≤-12≤k≤26,46≤I≤46
Reflections collected 90625
Independent reflections 26303 [R(int) = 0.0463]
Completeness to theta = 39.60° 96.1%
Absorption correction SADABS (Bruker-Nonius)
Max. and min. transmission 0.9686 and 0.9386
Refinement method Full-matrix least- squares o n F2
Data / restraints / parameters 26303 / 0 / 598
Goodness- of-fit on F2 1.034
Final R indices [1>2sigma(I)] R1 = 0.0514, wR2 = 0.1380
R indices (all data) R1 = 0.0677, wR2 = 0.1533
Largest diff. peak and hole 0.943 and -0.742 e. Å-3
Table 2. Bond lengths [Å] and angles [°]
Si (1)- 1.6358 (6) C(1)-O(2) 1.4195 (8) C(13)
O (1) C(1)-C(2) 1.5378 (9) Si(2)- 1.8721(10)
Si (1)-O(2) 1.6712 (6) C(1)-C(3) 1.5447(10) C(17)
Si (1)-C(7) 1.8662 (9) N(1)- 1.1492(13) C(2)-O(3) 1.4142 (8)
Si (1)- 1.8798 (8) C(27) C (2)-C(6) 1.5305(10)
C(10) Si(2)-O(3) 1.6557 (6) N(2)- 1.3702(11)
O (1)-Si(2) 1.6420 (6) Si(2)- 1.8659 (9) C(29)
N(2)-O(9) 1.3842 (9) C(7)-C(8) 1.5387(13) C(31)
N(2)-C(6) 1.4861 (9) O(7)- 1.2120(11) C(31)- 1.3930(12)
C(3)-O(4) 1.4328 (9) C(20) C (36)
C(3)- 1.5341(11) O(8)- 1.2172(10) C(31)- 1.3940(14)
C(19) C(29) C (32)
C(3)-C(4) 1.5564(11) O(9)- 1.4535(10) C(32)- 1.3974(17)
Si (3)- 1.6854 (7) C(30) C (33)
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(continued)
O (10) C(10)- 1.5359(13) C(33)- 1.3900(18)
Si (3)- 1.863 (2) C(11) C (34)
C(38) C(10)- 1.5396 (14) C(34)- 1.384 (2)
Si (3)- 1.876 (2) C(12) C (35)
C(37) C(13)- 1.5313 (15) C(35)- 1.3942(16)
Si (3)- 1.876 (5) C(15) C (36)
C(39) C(13)- 1.5407 (17) C(39)- 1.534 (4)
Si (3’)- 1.7189 (7) C(14) C(41)
O (10) C(16)- 1.5411(15) C(39)- 1.539 (5)
Si (3’)- 1.858 (2) C(17) C(40)
C(38’) C(17)- 1.5325(15) C(39)- 1.566(10)
Si (3’)- 1.876 (2) C(18) C(42)
C(37’) C(20)- 1.4868(11) C(39’)- 1.501(10)
Si (3’)- 1.878 (6) C(21) C(42’)
C(39’) C(21)- 1.3950(12) C(39’)- 1.504 (7)
C(4)- 1.4098 (9) C(26) C (41’)
O (10) C(21)- 1.3998 (11) C(39’)- 1.524 (7)
C(4)-C(5) 1.5601(11) C(22) 1.3946 (13) C(40’)
C(5)-O(5) 1.4219 (9) C(22)-
C(5)- 1.4872(12) C(23)
C(27) C(23)- 1.3915 (15)
C(5)-C(6) 1.5452(10) C(24)
C(6)- 1.5575(10) C(24)- 1.3896 (15) 5
C(28) C(25)
O (6)- 1.3581(11) C(25)- 1.3927 (14)
C(20) C(26)
O (6)- 1.4370(10) C(28)- 1.5315 (11)
C(19) C(29)
C(7)-C(9) 1.5322(15) C(30)- 1.5033 (13)
O (1)-Si(1)-O(2) 107.81 (3) O(1)-Si (1)-C(10) 107.58 (4)
O (1)-Si(1)-C(7) 111.13 (4) O(2)-Si (1)-C(10) 111.65 (3)
O (2)-Si(1)-C(7) 103.22 (3) C(7)-Si(1)-C(10) 115.24 (4)
Si (1)-O(1)-Si(2) 134.92 (4) C(27)-C (5)-C(6) 109.18 (7)
O (2)-C(1)-C(2) 111.75 (6) O(5)-C(5)-C(4) 111.25 (6)
O (2)-C(1)-C(3) 109.90 (5) C(27)-C (5)-C(4) 109.52 (7)
C(2)-C(1)-C(3) 112.44 (5) C(6)-C(5)-C(4) 111.21 (6)
O (1)-Si(2)-O(3) 108.19 (3) N(2)-C(6)-C(2) 110.94 (5)
O (1)-Si(2)-C(13) 108.05 (4) N(2)-C(6)-C(5) 113.04 (6)
O (3)-Si(2)-C(13) 104.61 (4) C(2)-C(6)-C(5) 110.36 (6)
O (1)-Si(2)-C(17) 106.28 (4) N(2)-C(6)-C(28) 85.95 (5)
O (3)-Si(2)-C(17) 111.90 (4) C(2)-C(6)-C(28) 115.65 (6)
C(13)-Si (2)-C(17) 117.49 (4) C(5)-C(6)-C(28) 118.65 (6)
C(1)-O(2)-Si (1) 121.94 (4) C(20)-O (6)-C(19) 114.78 (7)
O (3)-C(2)-C(6) 107.16 (6) C(9)-C(7)-C(8) 110.81 (8)
O (3)-C(2)-C(1) 112.68 (5) C(9)-C(7)-Si (1) 112.65 (7)
C(6)-C(2)-C(1) 112.47 (5) C(8)-C(7)-Si (1) 115.42 (7)
C(29)-N(2)-O(9) 125.28 (7) N(2)-O(9)-C(30) 110.41 (6)
C(29)-N(2)-C(6) 95.06 (6) C(11)-C (10)-C(12) 109.02 (8)
O (9)-N(2)-C(6) 124.86 (6) C(11)-C (10)-Si (1) 110.35 (7)
C(2)-O(3)-Si (2) 129.79 (5) C(12)-C (10)-Si (1) 114.81 (6)
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(continued)
O (4)-C(3)-C(19) 110.50 (6) C(4)-O(10)-Si (3) 129.91 (5)
O (4)-C(3)-C(1) 109.40 (6) C(4)-O(10)-Si (3’) 122.21 (5)
C(19)-C(3)-C(1) 107.34 (6) Si(3)-O (10)-Si (3’) 23.60 (2)
O (4)-C(3)-C(4) 103.07 (6) C(15)-C (13)-C(14) 109.46 (9)
C(19)-C(3)-C(4) 111.86 (7) C(15)-C (13)-Si (2) 113.98 (8)
C(1)-C(3)-C(4) 114.63 (6) C(14)-C (13)-Si (2) 109.99 (6)
O (10)-Si (3)-C(38) 106.57 (7) C(18)-C (17)-C(16) 111.29 (9)
O (10)-Si (3)-C(37) 115.66 (7) C(18)-C (17)-Si (2) 115.44 (8)
C(38)-Si (3)-C(37) 109.41(11) C(16)-C (17)-Si (2) 110.07 (8)
O (10)-Si (3)-C(39) 105.15(14) O(6)-C(19)-C(3) 110.39 (7)
C(38)-Si (3)-C(39) 112.18(14) O(7)-C(20)-O(6) 123.36 (8)
C(37)-Si (3)-C(39) 107.91(14) O(7)-C(20)-C(21) 124.07 (8)
O (10)-Si (3’)-C(38’) 108.22 (7) O(6)-C(20)-C(21) 112.56 (7)
O (10)-Si (3’)-C(37’) 116.06 (8) C(26)-C (21)-C(22) 120.19 (8)
C(38’)-Si(3’)-C(37’) 105.47(15) C(26)-C (21)-C(20) 117.21 (7)
O (10)-Si (3’)-C(39’) 104.04(18) C(22)-C (21)-C(20) 122.56 (7)
C(38’)-Si(3’)-C(39’) 112.12(18) C(23)-C (22)-C(21) 119.71 (8)
C(37’)-Si(3’)-C(39’) 111.1 (2) C(24)-C (23)-C(22) 119.85 (9)
O (10)-C (4)-C(3) 112.92 (7) C(25)-C (24)-C(23) 120.45 (9)
O (10)-C (4)-C(5) 109.20 (6) C(24)-C (25)-C(26) 120.05 (9)
C(3)-C(4)-C(5) 109.79 (5) C(25)-C (26)-C(21) 119.74 (9)
O (5)-C(5)-C(27) 105.40 (6) N(1)-C(27)-C(5) 178.24(13)
O (5)-C(5)-C(6) 110.11 (6) C(29)-C (28)-C(6) 86.08 (5)
O (8)-C(29)-N(2) 132.48 (8) C(41)-C (39)-C(40) 108.5 (3)
O (8)-C(29)-C(28) 136.34 (8) C(4 1)-C(39)-C(42) 107.5 (3)
N(2)-C(29)-C(28) 91.16 (6) C(40)-C (39)-C(42) 109.6 (4)
O (9)-C(30)-C(31) 106.72 (7) C(41)-C (39)-Si (3) 112.9 (3)
C(36)-C(31)-C(32) 119.01 (9) C(40)-C (39)-Si (3) 110.6 (2)
C(36)-C(31)-C(30) 120.44 (9) C(42)-C (39)-Si (3) 107.7 (4)
C(32)-C(31)-C(30) 120.55 (8) C(42’)-C(39’)-C(41’) 110.3 (5)
C(31)-C(32)-C(33) 120.52(10) C(42’)-C(39’)-C(40’) 107.0 (5)
C(34)-C(33)-C(32) 119.97(11) C(41’)-C(39’)-C(40’) 108.4 (6)
C(35)-C(34)-C(33) 119.67(10) C(42’)-C(39’)-Si(3’) 110.8 (5)
C(34)-C(35)-C(36) 120.49(10) C(41’)-C(39’)-Si(3’) 109.9 (4)
C(31)-C(36)-C(35) 120.32(10) C(40’)-C(39’)-Si(3’) 110.3 (4)
Table 3. Torsion angles [°]
O(2)-Si (1)-O(1)-Si (2) 6.76 (7) O(4)-C(3)-C(4)-O(10) 169.08 (6)
C(7)-Si(1)-O(1)-Si (2) -105.68(6) C(19)-C(3)-C(4)-O(10) 50.36(8)
C(10)-Si(1)-O (1)-Si(2) 127.30(6) C(1)-C(3)-C(4)-O(10) -72.13 (8)
Si(1)-O (1)-Si(2)-O(3) 10.22(7) O(4)-C(3)-C(4)-C(5) -68.80 (7)
Si(1)-O (1)-Si(2)-C(13) 122.95 (6) C(19)-C(3)-C(4)-C(5) 172.48 (6)
Si(1)-O (1)-Si(2)-C(17) - 110.11(6) C(1)-C(3)-C(4)-C(5) 49.99 (8)
C(2)-C(1)-O(2)-Si(1) -96.90(6) O(10)-C(4)-C (5)-O(5) -168.11 (6)
C(3)-C(1)-O(2)-Si(1) 137.54(5) C(3)-C(4)-C(5)-O(5) 67.59 (7)
O(1)-Si (1)-O(2)-C(1) 45.00(6) O(10)-C(4)-C (5)-C(27) - 52.00 (8)
C(7)-Si(1)-O(2)-C(1) 162.67(6) C(3)-C(4)-C(5)-C(27) - 176.30 (6)
C(10)-Si(1)-O (2)-C(1) -72.96(6) O(10)-C(4)-C (5)-C(6) 68.76 (8)
O(2)-C(1)-C(2)-O(3) 47.74(8) C(3)-C(4)-C(5)-C(6) -55.54 (8)
C(3)-C(1)-C(2)-O (3) 171.88(6) C(29)-N(2)-C(6)-C(2) - 105.61 (6)
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O(2)-C(1)-C(2)-C(6) -73.52(7) O(9)-N(2)-C(6)-C(2) 34.60 (9)
C(3)-C(1)-C(2)-C (6) 50.62(8) C(29)-N(2)-C(6)-C(5) 129.82 (6)
C(6)-C(2)-O(3)-Si(2) 167.26(5) O(9)-N(2)-C(6)-C(5) -89.97 (8)
C(1)-C(2)-O(3)-Si(2) 43.03(8) C(29)-N(2)-C(6)-C(28) 10.34 (6)
O(1)-Si (2)-O(3)-C(2) - 66.37(7) O(9)-N(2)-C(6)-C(28) 150.54 (7)
C(13)-Si(2)-O (3)-C(2) 178.62(6) O(3)-C(2)-C(6)-N(2) 52.72 (7)
C(17)-Si(2)-O (3)-C(2) 50.38(7) C(1)-C(2)-C(6)-N(2) 177.08 (6)
O(2)-C(1)-C(3)-O(4) -167.52(6) O(3)-C(2)-C(6)-C(5) 178.80 (5)
C(2)-C(1)-C(3)-O (4) 67.32(8) C(1)-C(2)-C(6)-C(5) -56.84 (7)
O(2)-C(1)-C(3)-C(19) - 47.59(8) O(3)-C(2)-C(6)-C(28) -43.01 (7)
C(2)-C(1)-C(3)-C (19) -172.75(6) C(1)-C(2)-C(6)-C(28) 81.35 (7)
O(2)-C(1)-C(3)-C(4) 77.32(7) O(5)-C(5)-C(6)-N(2) 60.87 (8)
C(2)-C(1)-C(3)-C (4) - 47.84(8) C(27)-C(5)-C(6)-N(2) - 54.39 (8)
C(4)-C(5)-C(6)-N (2) - 175.35(6) Si (3)
O(5)-C(5)-C(6)-C(2) -64.02(7) C(37’)-Si(3’)-O(10)- - 172.25 (17)
C(27)-C(5)-C(6)-C(2) -179.28(6) Si (3)
C(4)-C(5)-C(6)-C (2) 59.76(7) C(39’)-Si(3’)-O(10)- 65.41 (17)
O(5)-C(5)-C(6)-C(28) 159.20 (6) Si (3)
C(27)-C(5)-C(6)-C(28) 43.94(9) O(1)-Si(2)-C(13)-C(15) 173.08 (8)
C(4)-C(5)-C(6)-C (28) - 77.02(8) O(3)-Si(2)-C(13)-C(15) -71.81 (9)
O(1)-Si (1)-C(7)-C(9) -171.19(7) C(17)-Si (2)-C(13)- 52.95(9)
O(2)-Si (1)-C(7)-C(9) 73.49(8) C(15)
C(10)-Si(1)-C(7)-C(9) - 48.50(8) O(1)-Si(2)-C(13)-C(14) -63.55 (7)
O(1)-Si (1)-C(7)-C(8) -42.53(8) O(3)-Si(2)-C(13)-C(14) 51.55 (7)
O(2)-Si (1)-C(7)-C(8) -157.85(7) C(17)-Si (2)-C(13)- 176.32(7)
C(10)-Si(1)-C(7)-C(8) 80.16(8) C(14)
C(29)-N(2)-O(9)-C(30) - 119.66(8) O(1)-Si(2)-C(17)-C(18) 170.99 (7)
C(6)-N(2)-O(9)-C(30) 111.69 (8) O(3)-Si(2)-C(17)-C(18) 53.09 (8)
O(1)-Si (1)-C(10)-C(11) 77.42(8) C(13)-Si (2)-C(17)- - 67.95 (9)
O(2)-Si (I)-C (10)-C(11) - 164.49(7) C(18)
C(7)-Si(1)-C(10)-C (11) - 47.15(8) O(1)-Si(2)-C(17)-C(16) -62.00 (8)
O(i)-Si (1)-C(10)-C(12) - 46.25(7) O(3)-Si(2)-C(17)-C(16) -179.90 (7)
O(2)-Si (1)-C(10)-C(12) 71.84(7) C(13)-Si (2)-C(17)- 59.06(9)
C(7)-Si(1)-C(10)-C (12) -170.82(7) C(16)
C(3)-C(4)-O(10)-Si (3) -98.37(8) C(20)-O(6)-C (19)-C(3) 97.88 (9)
C(5)-C(4)-O(10)-Si (3) 139.18(7) O(4)-C(3)-C(19)-O(6) -40.01 (10)
C(3)-C(4)-O(10)-Si (3’) -126.11(7) C(1)-C(3)-C(19)-O(6) - 159.23 (7)
C(5)-C(4)-O(10)-Si (3’) 111.44(7) C(4)-C(3)-C(19)-O(6) 74.21 (9)
C(38)-Si(3)-O (10)-C (4) - 35.81 (13) C(19)-O(6)-C (20)-O (7) 4.86 (13)
C(37)-Si(3)-O (10)-C (4) 86.03 (12) C(19)-O(6)-C (20)- - 174.67 (7)
C(39)-Si(3)-O (10)-C (4) - 155.06 (13) C(21)
C(38)-Si(3)-O (10)- 43.88 (10) O(7)-C(20)-C (21)- 3.29 (14)
Si(3’) C(26)
C(37)-Si(3)-O (10)- 165.72 (11) O(6)-C(20)-C (21)- - 177.18 (8)
Si(3’) C(26)
C(39)-Si(3)-O (10)- - 75.37 (12) O(7)-C(20)-C (21)- - 174.41 (10)
Si(3’) C(22)
C(38’)-Si (3’)-O(10)- 62.90(13) O(6)-C(20)-C (21)- 5.12 (12)
C(4) C(22)
C(37’)-Si (3’)-O(10)- -55.36 (17) C(26)-C(21)-C(22)- - 0.42 (13)
C(4) C(23)
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(continued)
C(39’)-Si (3’)-O(10)- -177.71 (18) C(20)-C(21)-C(22)- 177.21 (8)
C(4) C(23)
C(38’)-Si (3’)-O(10)- -53.99 (11) C(21)-C(22)-C(23)- 0.04 (14)
C(24) C(35)
C(22)-C(23)-C (24)- 0.21 (16) C(34)-C(35)-C(36)- - 1.10 (17)
C(25) C(31)
C(23)-C(24)-C (25)- 0.09 (17) O(10)-Si (3)-C(39)- 55.4 (3)
C(26) C(41)
C(24)-C(25)-C (26)- - 0.28 (17)
C(21) C(38)-Si (3)-C(39)- -60.1 (3)
C(22)-C(21)-C (26)- 0.53 (15) C(41)
C(25) C(37)-Si (3)-C(39)- 179.3 (2)
C(20)-C(21)-C (26)- -177.22(9) C(41)
C(25) O(10)-Si (3)-C(39)- -66.3 (3)
0(5)-C (5)-C(27)-N (1) - 41 (4) C(40)
C(6)-C(5)-C(27)-N(1) 77(4) C(38)-Si (3)-C(39)- 178.2 (2)
C(4)-C(5)-C(27)-N(1) - 161(4) C(40)
N(2)-C(6)-C(28)-C(29) - 9.22 (5) C(37)-Si (3)-C(39)- 57.6 (3)
C(2)-C(6)-C(28)-C(29) 102.09(6) C(40)
C(5)-C(6)-C(28)-C(29) -123.32(6) O(10)-Si (3)-C(39)- 173.9 (3)
O(9)-N(2)-C(29)-O (8) 27.81 (14) C(42)
C(6)-N(2)-C(29)-O(8) 167.77(9) C(38)-Si (3)-C(39)- 58.5 (3)
O(9)-N(2)-C(29)-C(28) - 150.45(7) C(42)
C(6)-N(2)-C(29)-C(28) - 10.49(6) C(37)-Si (3)-C(39)- -62.1 (3)
C(6)-C(28)-C(29)-O(8) - 168.15 (10) C(42)
C(6)-C(28)-C(29)-N (2) 9.99 (6) O(10)-Si (3’)-C(39’)- - 166.9 (4)
N(2)-O(9)-C(30)-C(31) - 162.46(7) C(42’)
O(9)-C(30)-C(31)- -127.97(9) C(38’)-Si(3’)-C(39’)- -50.2 (5)
C(36) C(42’)
O(9)-C(30)-C(31)- 51.57 (11) C(37’)-Si(3’)-C(39’)- 67.5 (5)
C(32) C(42’)
C(36)-C(31)-C (32)- 1.45 (15) O(10)-Si (3’)-C(39’)- -44.7 (4)
C(33) C(41’)
C(30)-C(31)-C (32)- -178.09 (10) C(38’)-Si(3’)-C(39’)- 72.0 (4)
C(33) C(41’)
C(31)-C(32)-C (33)- - 1.30 (17) C(37’)-Si(3’)-C(39’)- - 170.3 (3)
C(34) C(41’)
C(32)-C(33)-C (34)- - 0.06 (18) O(10)-Si (3’)-C(39’)- 74.8 (4)
C(35) C(40’)
C(33)-C(34)-C (35)- 1.26 (18) C(38’)-Si(3’)-C(39’)- - 168.5 (4)
C(36) C(40’)
C(32)-C(31)-C (36)- - 0.26 (15) C(37’)-Si(3’)-C(39’)- -50.8 (5)
C(35) C(40’)
C(30)-C(31)-C (36)- 179.28 (10)
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Rf= 0.16 (TLC, hexane/AcOEt 3:1); yield, 10%; white solid;
1H- NMR (300 MHz CDCl3): δ 7.46- 7.43 (2H, m, Ph), 7.39-7.35 (3H, m, Ph), 5.17 (1H, part A syst. AB, J = 10.7 Hz,
OCH2Ph), 5.12 (1H, part B syst. AB, J = 10.7 Hz, OCH2Ph), 4.86 (1 H, br. s, OH), 4.81 (1H, d, J = 4.8 Hz), 4.36 (1 H,
d, J = 4.8 Hz), 4.14 (2H, s, CH2OH), 4.06 (1 H, br. s, OH), 3.98 (1 H, dd, J = 10.3, 5.3 Hz), 3.66 (1H, dd, J = 10.3, 3.4
Hz), 3.30 (1H, partA syst. AB, J = 14.8 Hz, H- 3), 2.87 (1H, part B syst. AB, J = 14.8 Hz, H-3’), 2.10 (1H, br. s), 1.13-1.01,
(28H, m, TIPDS), 0.93 (9H, s, C (CH3)3), 0.29 (3H, s, SiCH3), 0.22 (3H, s, SiCH3); 
13C-NMR (75 MHz, CDCl3): 167.1, 135.5, 129.9, 129.0, 128.9, 128.6, 128.4, 117.9, 79.4, 78.7, 77.2, 75.1, 73.6, 68.0,
65.1, 63.7, 38.5, 26.4, 17.8, 17.5, 17.4, 17.3, 17.2, 17.1,16.9,13.9,13.0,12.9;
LMRS(API-ES+): m/z 737 (M+H)+, 738 (M+2H)+, 739 (M+3H)+, 759 (M+Na)+, 760 (M+Na+H)+; 783 (M+2Na+H)+; 1497
(2M+Na+2H)+.
Example 5: compounds of formula (Ib) and Epimerization
Preparation of rac- (4S, SR, 6S, 7R, 8S, 9S)- 1-benzyloxy- 7-(benzyloxymethyl)- 6-(tert- butyldimethylsililoxi)- 
5,8,9-trihydroxy- 8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-azaspiro[3.5] non-2-ona-5,7-carbolactone 
(10) and rac-(4R, 5R, 6R, 7S, 8S, 9S)- 1-benzyloxy- 7-(benzoyloxymethyl)-6-(tert- butyldimethylsilyloxy)-5,7-O-di-
tert-butylsiloxane-5-cyano- 5,7,8,9-tetrahydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-azaspiro 
[3.5]nonan- 2-one (11)
[0116]
[0117] To a stirred solution of rac-(4R,5R, 6R, 7S, 8S, 9S)- 1-benzyloxy-7-(benzoyloxy methyl)-6-(tert-butyldimethylsily-
loxy)- 5-cyano-5,7,8,9-tetrahydroxy -8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)-1-azaspiro [3.5] nonan-2-one (7)
(50 mg, 0.060 mmol) in CH2Cl2 (2 ml) at 0° C was added triethylamine (20Pl, 0.143 mmol) and di-tert-butylsilyl bis
(trifluomethane)sulfonate (22Pl, 0.065 mmol). The resulting mixture was stirred at room temperature for 17 hours. The
reaction was quenched at 0° C with Na2PO4 (0.1 M buffer, 3 ml) and the mixture extracted with AcOEt (3 x 5 ml). The
combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (hexane/AcOEt, 8:1) to give rac-(4S, 5R, 6S, 7R, 8S, 9S)- 1-benzyloxy- 7-(ben-
zyloxymethyl)-6-(tert-butyldimethylsililoxi)-5,8,9-trihydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro
[3.5] non- 2-ona- 5,7-carbolactone (10) (30 mg, 33%) as a white solid (24 mg, 48%) and rac-(4R, 5R, 6R, 7S, 8S, 9S)-1-
benzyloxy- 7-(benzoyloxymethyl)- 6-(tert-butyldimethylsilyloxy)-  5,7-O-di-  tert-  butylsiloxane-  5- cyano- 5,7,8,9- tetrahy-
droxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro [3.5] nonan-2-one (11) (17 mg, 29%).
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Rf= 0.14 (TLC, hexane/AcOEt 4:1); yield, 48%; white solid;
1H- NMR (300 MHz CDCl3): δ 8.02 (2H, dm, J = 7.1 Hz, Bz), 7.61 (1H, t, J = 7.3 Hz, Bz), 7.47 (2H, dd, J = 7.3 Hz, Bz),
7.43-7.25 (5H, m, Ph), 5.16 (1H, part A syst. AB, J = 9.8 Hz, OCH2Ph), 5.08 (1H, part B syst. AB, J = 9.8 Hz, OCH2Ph),
4.69 (1H; part A syst. AB, J = 12.4 Hz, H-4), 4.67 (1H, d, J = 3.4 Hz, H- 9), 4.57 (1H, part B syst. AB,, J = 12.4, Hz, H-
10’), 4.56 (1H, d, J = 3.4 Hz, H- 8), 4.49 (1H, s, H-6), 3.31 (1H, br.s, OH), 3.14 (1H, part A syst. AB, J = 14.4 Hz, H- 3),
3.03 (1H, part B syst. AB, J = 14.4 Hz, H- 3’), 1.16-0.80 (28H, m, TIPDS), 0.90 (9H, s, C (CH3)3), 0.16 (3H, s, SiCH3),
0.12 (3H, s, SiCH3);
IR (film): ν 3435, 3062, 3032, 2962, 2925, 2867, 1769, 1729, 1663, 1601, 1465, 1387, 1313, 1262,1099, 1015, 885,
801, 736, 696 cm-1 ; 
LMRS(API-ES+): m/z 841 (M)+, 842 (M+H)+, 843 (M+2H)+, 864 (M+Na)+, 1705 (2M+Na)+. 
X-ray Diffaction of rac-(4S, 5R, 6S, 7R, 8S, 9S)-1-benzyloxy-7-(benzyloxymethyl)-6-(tert- butyldimethylsililoxi)-
5,8,9-trihydroxy- 8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3- diyl)- 1-azaspiro [3.5]non- 2-ona-5,7-carbolactone
(10)
[0118] A solution rac-(4S, 5R, 6S, 7R, 8S, 9S)- 1- benzyloxy-7-(benzyloxymethyl)-6-(tert- butyldimethylsililoxi)- 5,8,9-trihy-
droxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1- azaspiro [3.5] non-2- ona-5,7-carbolactone (10) in AcOEt (24
mM, 0.5 ml disol.) was crystallized by hexane diffusion.
[0119] The crystal was placed on a Mar345 diffractometer equipped with a image-plate detector. The determination
of unit cell parameters and data collections were performed with MoKa radiation using a graphite monochromator. The
program used for evaluation was WINGX, the intensities were corrected using Lorente-polarization factor. The structure
was solved by direct methods using the SHELXL-97 program. Final refinement was performed by full-matrix least-
squares methods. Crystallographic data and experimental details for structural analyses are summarized in Table 4,
whereas positional parameters and atomic coordinates are given in Table 5. Figure 2 is a representation of the molecular
structure obtained using X-rays diffraction.
Table 4. Crystal data and structure
Empirical formula C42H63NO11Si3
Formula weight 842.20
Temperature 293 (2) K
Wavelength (Å) 0.71073
Crystal system, space group Monoclinic, P21/a
Unit cell dimensions a = 15.706(6) Å
b=16.444 (5)
c = 19.902 (6)
β = 107.62 (2)"
Volume 4899 (3) Å3
Z, Calculated density 4, 1.142 Mg/m3
P (mm-1) 0.149
F (000) 1808
Crystal size 0.3 x 0.2 x 0.2 mm
θ range for data collection 3.44 to 32.98°
Reflections collected / unique 42348 / 12584 [R (int) = 0.0434]
Goodness-of- fit on F2 1.070
Final R indices [I>2sigma (I)] R1 = 0.0569, wR2 = 0.1856
R indices (all data) R1 = 0.0875, wR2 = 0.2066
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Table 5. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2 x 103). U (eq) is defined 
as one third of the trace of the orthogonalized Uij tensor.
x y z U(eq)
Si (2) 1874(1) 4420(1) 4123(1) 61 (1)
Si (3) -178 (1) 7035(1) 2366(1) 62(1)
Si (1) 2977 (1) 3674 (1) 3284 (1) 64 (1)
O(1) 2489(1) 4341 (1) 2669(1) 58 (1)
O(2) 1275(1) 4851 (1) 3370(1) 51 (1)
0 (3) 2622(1) 3841 (1) 3964 (1) 65 (1)
0 (5) -1521(1) 4668 (1) 2257(1) 66(1)
0 (6) - 2013(1) 5059(1) 3161(1) 95 (1)
O(7) 330 (1) 6137 (1) 2398(1) 53(1)
0 (8) 2233(1) 4286(1) 1063(1) 57 (1)
O(9) 3384(1) 5749(1) 1643(1) 78 (1)
O(10) -256 (1) 4111(1) 1714(1) 51 (1)
O(11) 293 (1) 5861(1) 864 (1) 48 (1)
0 (12) - 255 (1) 4172(1) 552(1) 75(1)
N 1989(1) 5026(1) 1289(1) 50(1)
C(1) 1573(1) 4379(1) 2283(1) 47 (1)
C(2) 950 (1) 4386(1) 2751(1) 48 (1)
C(3) -3(1) 4664 (1) 2319(1) 47 (1)
C(4) -51(1) 5485(1) 1945(1) 45 (1)
C(5) 439 (1) 5255(1) 1402 (1) 42 (1)
C(6) 1443 (1) 5102(1) 1782(1) 42 (1)
C(7) 4178(2) 3890(2) 3527(2) 91 (1)
C(8) 4734 (2) 3465(3) 4181 (2) 105 (1)
C(9) 4610(2) 3599(3) 2928(2) 108 (1)
C(10) 2727 (2) 2620(2) 2978(2) 91 (1)
C(11) 2843(2) 2489(2) 2268(2) 99(1)
C(12) 1885 (2) 2332(2) 2918 (2) 104 (1)
C(13) 1096(2) 3743(2) 4437 (2) 87 (1)
C(14) 1619(2) 3093(2) 4985(2) 93(1)
C(15) 458 (2) 4222(2) 4698 (2) 92 (1)
C(16) 2388(2) 5275(2) 4696(2) 87 (1)
C(17) 2949(2) 5790(2) 4364 (2) 97 (1)
C(18) 2933(2) 4999(2) 5443(2) 97 (1)
C(19) -629 (2) 9577(2) 2731(2) 78 (1)
C(20) -2170(2) 4866(2) 2559(2) 72 (1)
C(21) -3060(2) 4856(2) 2045(2) 82 (1)
C(22) -3173(2) 4619(2) 1377 (2) 95(1)
C(23) -4072(2) 4552(2) 927 (2) 103(1)
C(24) -4732(2) 4857(2) 1290 (2) 102(1)
C(25) - 4594 (2) 5114 (2) 1908 (2) 96 (1)
C(26) -3741(2) 5070 (2) 2282(2) 92 (1)
C(27) 326(2) 7466(2) 3271 (2) 87 (1)
C(28) 270(2) 6902(2) 3821(2) 97 (1)
C(29) 1339(2) 7627 (2) 3313(2) 97 (1)
C(30) -78 (2) 8312(2) 3316(2) 95(1)
C(31) -1413(2) 6949(2) 2191(2) 90(1)
C(32) -1 (2) 7646(2) 1632 (2) 89(1)
C (33) 1919(1) 4264 (1) 295(1) 79(1)
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Rf = 0.59 (TLC, hexane/ AcOEt 4:1); yield, 29%; 
1H- NMR (300 MHz CDCl3): δ 8.05-8.02 (2H, m, Bz), 7.62-7.59 (1H, m, Bz), 7.49-7.43 (2H, m, Bz), 7.39-7.29 (5H, m,
Ph), 5.28 (1H, d, J = 4.8 Hz, H- 9), 5.17 (1H, part A syst. AB, J = 11.2 Hz, OCH2Ph), 5.06 (1H, part B syst. AB, J = 11.2
Hz, OCH2Ph), 4.88 (1H, br. s, H- 6), 4.76 (1H, part A syst. AB, J = 11.6 Hz, H-10), 4.64 (1H, part B syst. AB, J = 11.6Hz,
H-10’), 4.52 (1H, d, J=4.8Hz, H-8), 3.26 (1H, part A syst. AB, J = 14.6 Hz, H- 3), 2.88 (1H, part B syst. AB, J = 14.6 Hz,
H-3’), 1.16-0.94, (56H, m, TIPDS, TBDS), 0.36 (3H, s, SiCH3), 0.28 (3H, s, SiCH3);); 
13C-NMR (75 MHz, CDCl3): δ 167.2, 166.5, 135.5, 133.3, 129.8, 129.5, 128.4, 128.2, 128.1, 124.8, 118.1, 79.9, 78.5,
77.5, 77.2, 74.6, 73.4, 68.0, 66.6, 64.6, 39.0, 29.7, 28.5, 27.7, 27.6, 27.5, 26.8, 26.7, 26.3, 22.1, 21.4, 20.5, 20.4, 20.2,
18.7, 17.8, 17.4, 17.24, 17.22, 17.19, 17.13, 16.9, 14.9, 14.2, 13.2, 12.6, 12.2, 1.0;
LMRS (API- ES+): m/z 981 (M)+, 1004 (M+Na)+.
Example 6
Preparation of rac-(1’R, 4R, 5S, 6S, 7S, 8R, 9S)- 1-Benzylloxy- 8,10-(cyanophenylmethylendioxy)-5,6,7,9-tetrahy-
droxy- 7-methyl-5,6-O-(1,1,3,3-tetraisopropyldisyloxane- 1,3-diyl)- 1-azaspiro [3.5]nonan- 2one (12)
[0120]
[0121] To a solution of rac-(4R, 5S, 6S, 7S,8S, 9S)- 1-benzylloxy- 7-(benzoyloxymethyl)- 8,9-epoxi-5,6,7-trihydroxy-
5,6-O-(1,1,3,3-tetraisopropyldisylixane- 1,3-diyl)- 1-azaspiro[3.5] nonan- 2-one (3) (420 mg, 0.614 mmol, 1 eq) in toluene
(continued)
x y z U(eq)
C(34) 2339(1) 3530(1) 82 (1) 66(1)
C(35) 3078 (1) 3630(1) -156(1) 98 (1)
C(36) 3444 (2) 2958 (3) - 400(2) 109(1)
C(37) 3076(2) 2206(2) -374 (2) 96(1)
C(38) 2359(3) 2108 (2) -152 (2) 103(1)
C(39) 1982 (2) 2775(2) 82 (2) 97 (1)
C(40) 2614 (1) 5600(1) 1653 (1) 57 (1)
C(41) 2019(1) 5877(1) 2069(1) 52 (1)
C(42) -67 (1) 4469(1) 1154(1) 47 (1)
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(5 ml) was added, at 0°C, diethylaluminium cyanide (0.92 ml, disol. 1.0 M in toluene, 1.5 eq). The reaction mixture was
stirred for 17 hours at room temperature, after which, a mixture of potasium sodium 10% de tartrate aqueous solution-
EtOAc (1: 1, 4 ml). The mixture was then stirred 10 minutes, the phases separated and the aqueous phase extracted
with EtOAc (3 x 3 ml). The organic phase was dried with anhydrous Na2SO4, filtrated and the organic solvent evaporated
under reduced pressure to yield 422 mg (97 % yield before purification) of the title compound. The residue was purified
by chromatographic column (hexane/AcOEt, 4: 1) to yield rac-(1’R, 4R, 5S, 6S,7S, 8R, 9S)- 1-Benzyloxy-8,10-(cyanophe-
nylmethylendioxy)-5,6,7,9-tetrahydroxy-7-methyl-5,6-O-(1,1,3,3-tetraisopropyldysiloxane-1,3-diyl)-1-azaspiro[3.5] non-
an-2-one (12) (55 % yield) as a white solid.
rac- (1’R, 4R, 5S, 6S, 7S, 8R, 9S)-1-Benzyloxy- 8,10-(cyanophenylmethylendioxy)-5,6,7,9-tetrahydroxy- 7-methyl-
5,6-O-(1,1,3,3-tetraisopropyldysiloxane-1,3-diyl)-1-azaspiro [3.5] nonan-2-one (12)
[0122]
Rf= 0.35 (TLC, Hex: AcOEt 3:1). Yield 98%; white solid.
1H- NMR (200 MHz, CDCl3): δ 7.56- 7.51 (2H, m, Ph), 7.46- 7.31 (8H, m, Ph), 5.19 (1H, part. A syst.AB, J = 10.4 Hz),
5.08 (1H, part.B syst. AB, J = 10.4 Hz), 5.01 (1H, d, J = 3.7 Hz, H-5) 4.52 (1H, dd, J = 3.7, 1.5 Hz, H-6), 4.41 (1H, dd,
2.7, 1.6 Hz, H-8), 4.32 (1H, t, J = 3.3, 2.9 Hz, H-9), 4.22 (1H, part. A syst. AB, J =12.1 Hz, H- 11), 4.11 (1H, part. B
syst.AB, J = 12.1 Hz, H-11), 3.93 (3 H, s, OH(7)), 3.54 (1H, br. s, OH(9)), 3.11 (1H, part. A syst. AB, J = 14.28 Hz, H-
3), 2.34 (1H, part.B syst.AB, J = 14.28 Hz, H- 3) 1.10- 1.00 (28H, m, TIPDS).
13C-NMR (75MHz, CDCl3) δ 164.7, 135.6, 134.4, 130.3, 129.4, 129.2, 128.9, 128.3, 125.6, 114.5 (CN), 95.2, 79.2, 78.1,
76.7, 76.4, 70.7, 67.7, 65.8, 65.6, 37.3, 17.8, 17.6, 17.5, 17.2, 17.1, 16.8, 16.7, 16.6, 14.2, 13.1, 13.0.
IR (KBr): ν 3451, 2946, 2889, 2862, 2218, 1748, 1631, 1462, 1278, 1248, 1154, 1099 1055, 922, 883, 855, 804, 744,
695 cm-1. 
LMRS (API-ES+): m/z 1444 (2M+Na)+, 733 (M+Na)+, 711 (M+H)+, 684 (M-26)+. 
LMRS (EI): m/z 710 (M+, 0.2), 683 (0.5), 588 (1), 561 (1), 532 (1), 518 (1), 439 (1), 399 (2), 365 (2), 339 (7), 289 (5),
261 (6), 191 (4), 163 (4), 147 (6), 135 (11), 119 (8), 105 (98), 91 (100), 77 (19).
Preparation of rac- (1’R, 4S, 5S, 6S, 7S, 8R)-1-benzyloxy-8,10-(cyanofenylmethylendioxy) -5,6,7-trihydroxy- 7-me-
thyl-5,6-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)- 1-azaespiro[3.5] nonan- 2,9-dione (14) and rac-(1’R, 4S, 5S, 
6S, 7S, 8R)- 1-benciloxy- 8,10-(cyanofenylmethylendioxy)-5,6,7,9,9-pentahydroxy- 7-methyl-5,6-O-(1,1,3,3-tetrai-
sopropyldisiloxane- 1,3-diyl)- 1-azaespiro [3.5] nonan- 2one (15)
[0123]
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[0124] To a stirred solution of rac- (1’R, 4R, 5S, 6S, 7S, 8R, 9S)- 1- benciloxy-8,10-(cyanofenylmethylendioxy)-5,6,7,9-tet-
rahydroxy- 7- methyl- 5,6-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)-1-azaespiro [3.5] nonan- 2one (12) (200 mg, 0.242
mmol, 1 eq) in AcOEt (8 ml), at room temperature, was added IBX (237 mg, 3 eq). The resulting mixture was heated at
70°C for 3 hours. After this time, the mixture was filtered through Celite in vacuum and concentrated under reduced
pressure. To the result solid in AcOEt (8 ml), was added, at room teperature IBX (237 mg, 3 eq) and the mixture was
heated at 70°C. After 3 hours, the mixture was filtered again through Celite in vacuum and concentrated under reduced
pressure.suspension. To the result solid in AcOEt (8 ml), was added, at room temperature IBX (237 mg, 3 eq) and the
mixture was heated at 70°C for 3 hours. After this time, the mixture was filtered through Celite in vacuum and concentrated
under reduced pressure. To the solid product was added AcOEt (10 ml) and the mixture formed was washed with water
(2x 10 ml). The layers were separated. The organic layer was dried over Na2SO4, filtered and concentrated under
reduced pressure. To the solid was added diethyl ether (5 ml) and was sonicated by means of an ultrasound bath for 5
minutes. After this time, the solvent was evaporationed under reduced pressure. To the solid was added toluene (5 ml)
and was sonicated by means of an ultrasound bath for 5 minutes. After this time, the solvent was evaporationed under
reduced pressure. To the solid was added, diethyl ether (5 ml) and was sonicated by means of an ultrasound bath for
5 minutes. After this time, the solvent was evaporationed under reduced pressure. To the solid was added toluene (5
ml) and was sonicated by means of an ultrasound bath for 5 minutes. After this time, the solvent was evaporationed
under reduced pressure. To the solid was added diethyl ether (5 ml) and was sonicated by means of an ultrasound bath
for 5 minutes. After this time, the solvent was evaporationed under reduced pressure to give a mixture [10: 1] of rac-(1’R,
4S, 5S, 6S, 7S,8R)- 1- benzyloxy-8,10-(cyanofenylmethylendioxy)- 5,6,7-trihydroxy-7-methyl- 5,6-O-(1,1,3,3-tetraisopro-
pyldisiloxane- 1,3-diyl)-1- azaespiro [3.5] nonan- 2,9-dione (14) and rac-(1’R, 4S,5S,6S, 7S, 8R,)- 1-benciloxy- 8,10-(cy-
anofenylmethylendioxy)- 5,6,7,9,9- pentahydroxy- 7-methyl-  5,6-O-(1,1,3,3- tetraisopropyldisiloxane- 1,3- diyl)-  1- aza-
espiro[3.5] nonan- 2one (15) (179 mg, yield 90% ).
rac- (1’R, 4S, 5S, 6S, 7S, 8R)- 1-benzyloxy- 8,10-(cyanofenylmethylendioxy)- 5,6,7-trihydroxy- 7-methyl-
5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-azaespiro [3.5]nonan- 2,9-dione (14)
[0125]
1H- NMR (300 MHz, CDCl3): δ 7.60- 7.55 (2H, m, Ph), 7.45- 7.30 (8H, m, Ph), 5.16 (2H, s, OCH2Ph), 4.78 (1H, d, J =
3.7 Hz, H- 5) 4.62 (1H, d, J = 1.5 Hz, H- 8), 4.57 (1H, dd, 3.7, 1.5 Hz, H- 6), 4.38 (1H, part. A syst. AB, J =12.1 Hz, H- 10),
4.16 (1H, part. B syst.AB, J = 12.1 Hz, H- 10’), 3.36 (1H, part. A syst. AB, J = 13.8 Hz, H-3), 2.64 (1H, part.B syst.AB, J
= 13.8 Hz, H-3’) 1.13- 1.01 (28H, m, TIPDS). 
13C- NMR (75 MHZ, CDCl3): δ 198.5, 163.9, 135.4, 134.8, 130.6, 129.2,128.8, 128.4,
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128.3, 125.5, 114.1, 94.7, 81.2, 78.7, 76.5, 73.0, 70.5, 68.7, 65.2, 38.6, 17.8, 17.4, 17.3, 17.0, 16.9, 16.8, 16.7, 16.6.
LMRS(API-ES+): m/z 754 (M+2Na)+, 731 (M+Na)+, 708 M+.
rac- (1’R, 4S, 5S, 6S, 7S, 8R, 9S)- 1-benciloxy-8,10-(cyanofenylmethylendioxy)-5,6,7,9,9-pentahydroxy- 7-methyl-
5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-azaespiro [3.5]nonan- 2one (15)
[0126]
1H- NMR (300 MHz, CDCl3): δ 7.60- 7.55 (2H, m, Ph), 7.45- 7.30 (8H, m, Ph), 5.20 (1H, part.A syst. AB, J =10.6 Hz,
OCH2Ph), 5.03 (1H, part.B syst. AB, J = 10.6 Hz, OCH2Ph), 4.84 (1 H, d, J =3.5 Hz, H- 5) 4.54 (1 H, brs), 4.46 (1 H, dd,
J = 3.5, 1.3 Hz, H-6), 4.26 (1H, part.A syst.AB, J = 12.3 Hz, H- 10), 4.19 (1H, d, J = 1.3 Hz, H- 8), 4.11 (1H, part.B syst.AB,
J = 12.3 Hz, H- 10’), 2.98 (1H, part. A syst. AB, J =13.9 Hz, H- 3), 2.76 (1H, part. B syst.AB, J = 13.9 Hz, H-3’), 1.13- 1.01
(28H, m, TIPDS).
LMRS(API-ES+): m/z 754 (M+2Na)+, 731 (M+Na)+, 708 M+.
Preparation of rac-(4R, 5S, 6S, 7S, 8S, 9S)- 1-benzyloxy- 6,10-cyanophenylmethylendioxy -5,7,8,9-tetrahydroxy-
7-methyl-8,9-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)- 1-azaspiro [3.5] non- 2-ona (16)
[0127]
[0128] To a solution of rac-(4R,5R, 6S, 7R, 8S, 9S)-1- benzyloxy-5-carbonyl-6,10-cyanophenylmethylendioxy- 5,7,8-
trihydroxy-7-methyl-8,9-O-(1,1,3,3-tetraisopropyldi siloxane-1,3-diyl)- 1- azaspiro [3.5] non- 2-one (14) (90 mg, 0.130
mmol) in toluene (1 ml) was added, at 0 °C with vigorous stirring, a solution of diethylaluminium cyanide in toluene (1.0
M, 0.20 ml, 0.200 mmol) and the mixture was stirring to room temperature. After 14 hours, a mixture 10% aquous
potassium-sodium tartrate solution-AcOEt (1: 1, ml) was added. The layers were separated and aqueous phase was
extracted with AcOEt (3 x 3 ml). The combined organic extracts were dried over Na2SO4, filtered and concentrated under
reduced pressure to give rac-(4R, 5S, 6S, 7S, 8S, 9S)- 1-benzyloxy- 6,10-cyanophenylmethylendioxy -5,7,8,9- tetrahydroxy-
7-methyl- 8;9-O-(1,1,3,3-tetraisopropyl disiloxane-1,3-diyl)-1-azaspiro [3.5] non-2-ona (16) (70 mg, 73%) as a white solid. 
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Rf= 0.25 (TLC, hexane/AcOEt 3:1); yield, 73%; white solid.
1H- NMR (300 MHz, CDCl3): δ 7.55- 7.33 (10H, m, Ph), 5.18 (1H, part A syst. AB, J = 11.1 Hz, OCH2Ph), 5.01 (1H, part
B syst. AB, J = 11. Hz, OCH2Ph), 4.82 (1H, d, J = 3.6 Hz, H- 9), 4.48 (2H, br. s, H- 8 y H-6), 4.24 (1H, part A syst. AB, J
=12.2 Hz, H-10), 4.09 (1H, part B syst. AB, J = 12.2 Hz, H- 10’), 3.23 (1 H, part A syst. AB, J = 14.29 Hz, H- 3), 2.76 (1H,
part B syst. AB, J = 14.29 Hz, H-3’) 1.10- 1.00 (28H, m, TIPDS);
13C -NMR (75 MHz, CDCl3): δ 166.1, 134.8, 134.7, 130.6, 129.3, 129.2, 129.0, 128.9, 128.7, 128.6, 128.2, 125.4, 125.3,
115.4, 113.9, 95.1, 79.2, 77.5, 77.2, 70.2, 67.3, 65.7, 65.1, 38.2, 29.7, 17.7, 17.5, 17.4, 17.2, 17.0, 16.9, 16.8, 16.6,
16.5, 14.0, 13.4, 13.1, 12.9, 1.0;
LMRS (API- ES+): m/z 758 (M+Na)+, 759 (M+Na+H)+, 737 (M+2H)+, 736 (M+H)+. 
IR (film): ν 3435.8, 3065, 3034.2, 2959, 2947,2, 2866.0, 2344, 2244, 1760.9, 1624.0, 1453.2, 1261.7, 1105.2, 1008.9,
884.6, 800.7, 696.7
Example 9: General Formula I
Preparation of rac-(4S, 5R, 6S, 7R, 8S, 9S)- 1-benzyloxy- 7-(benzyloxymethyl)- 6-(tert-butyldimethylsililoxi)-
5,8,9-trihydroxy-8,9-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)- 1-azaspiro[3.5] non-2-ona-5,7-carbolactone 
(10)
[0129]
[0130] To a stirred solution of rac-(4S, 6S,7R, 8S, 9S)- 1-bencyloxy-7-benzoiloximetil-6-tert- butildimetilsililoxi- 7,8,9-
trihydroxy-8,9-O-( 1,1,3,3-tetraisopropildisiloxano-1,3-diyl)-1-azaespiro[3.5] nonano-2,5-diona (1) (92 mg, 0.113 mmol)
and trimethylsilyl cyanide (29 Pl, 0.216 mmol) in THF (1 ml) at room temperature was slowly added DABCO (1 mg, 0.01
1 mmol). The mixture was stirred at room temperature for 15 h and then concentrated under reduced pressure. The
residue was purified by silica gel column chromatography (hexane-AcOEt, 10:1) to give rac-(4S, 5R, 6S, 7R,8S, 9S)- 1-
benzyloxy- 7-(benzyloxymethyl)- 6-(tert-butyldimethylsililoxi)- 5,8,9- trihydroxy- 8,9-O-(1,1,3,3- tetraisopropyldisiloxane-
1,3- diyl)-1-azaspiro[3.5]non- 2- ona- 5,7-carbolactone (10) (30 mg, 33%) as a white solid.
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Rf = 0.30 (TLC, hexane/ AcOEt, 1:1); yield, 33%; white solid;
1H- NMR (300 MHz, CDCl3): δ 8.02 (2H, dm, J = 7.1 Hz, Bz), 7.61 (1H, t, J = 7.3 Hz, Bz), 7.47 (2H, dd, J = 7.3 Hz, Bz),
7.43-7.25 (5H, m, Ph), 5.16 (1H, part A syst. AB, J = 9.8 Hz, OCH2Ph), 5.08 (1H, part B syst. AB, J = 9.8 Hz, OCH2Ph),
4.69 (1H, part A syst. AB, J = 12.4 Hz, H- 4), 4.67 (1H, d, J = 3.4 Hz, H-9), 4.57 (1H, part B syst. AB,, J = 12.4, Hz, H-
10’), 4.56 (1H, d, J = 3.4 Hz, H-8), 4.49 (1H, s, H- 6), 3.31 (1H, br.s, OH), 3.14 (1H, part A syst. AB, J = 14.4 Hz, H- 3),
3.03 (1H, part B syst. AB, J = 14.4 Hz, H- 3’), 1.16-0.80 (28H, m, TIPDS), 0.90 (9H, s, C (CH3)3), 0.16 (3H, s, SiCH3),
0.12 (3H, s, SiCH3);
IR (film): ν 3435, 3062, 3032, 2962, 2925, 2867, 1769, 1729, 1663, 1601, 1465, 1387, 1313, 1262, 1099, 1015, 885,
801, 736, 696 cm-1; 
LMRS (API- ES+): m/z 1705 (2M+Na)+, 864 (M+Na)+, 841 (M)+.
Claims
1. A compound of formula (I)
wherein
R1 is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkyl-OPr, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl and NReRf, wherein Re and Rf are each independently selected
from H, OH, OPr, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or un-
substituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino and halogen; and
R3 is selected from hydrogen, OH, OPr or =O; or
R1 and R3 together form a group selected from -CH2-O- Pr-O- and -CH2-O- C(R11R12)-O-, the oxygen terminus
being attached to the C6 carbon atom; wherein R11 is selected from the group consisting of substituted or
unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or
unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkoxy, substituted or un-
substituted aryloxy,; and
R12 is selected from the group consisting of cyano, substituted or unsubstituted alkyl and aziridine;
R9 and R10 are each independently selected from hydrogen, OH, OPr and =O;
R5 is selected from the group consisting of hydrogen, -CN,-OH, OPr and a carbonyl derivative of formula -C
(=O) Rg, wherein Rg is a selected form the group consisting of hydrogen, substituted or unsubstituted alkoxy,
substituted or unsubstituted aryloxy and substituted or unsubstituted amine;
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L is selected from the group consisting of
• -O-C(=X)-, wherein X is selected from NPrn, NH or O, and the carbon atom supporting X is attached to
C5; and
• Z, wherein Z is selected from the group consisting of -O- C(R6R7)-O-, -O-Si(R6R7)-O- and -O-Si (R6R7)-O-
Si (R6R7)-O-, wherein each of R6 and R7 are independently selected from the group consisting of hydrogen,
substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alke-
nyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted
heterocyclyl;
W is selected from the group consisting of -H, substituted or unsubstituted alkyl, substituted or unsubstituted
aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl and substituted or unsubsti-
tuted alkenyl;
Ra and Rb are each independently selected from H, OH, OPr, substituted or unsubstituted alkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted
or unsubstituted amino and halogen;
Pr is a hydroxyl protecting group; and
Pm is an amino protecting group;
or its tautomers, salts or solvates thereof.
2. A compound according to claim 1, of formula (Ia) 
wherein
R1, R3, R9, R10, Ra, Rb, W and X are as defined in claim 1; and
R5 is selected from the group consisting of hydrogen, -OH or OPr;
or its tautomers, salts or solvates thereof.
3. A compound according to claim 1, of formula (Ib) 
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wherein
R1, R3, R9, R10, Ra, Rb, Z and W are as defined in claim 1;
or its tautomers, salts or solvates thereof.
4. A compound according to any of the previous claims, wherein R1 and R3 together are -CH2-O- Pr-O-, wherein Pr is
a hydroxyl protecting group.
5. A compound according to any of claims 1, 2 and 3, wherein R1 and R3 together are -CH2-O-C(R11R12)-O-.
6. A compound according to claim 5, wherein R11 is substituted or unsubstituted aryl.
7. A compound according to any of claims 5, 6 and 7, wherein R12 is cyanide.
8. A compound according to any of the previous claims, wherein R9 and R10 together are -O-Pr-O-, wherein Pr is a
hydroxyl protecting group.
9. A compound according to claim 2 of formula (Ia’) 
wherein R5, R11, Ra, X, Pr and W are defined as in claim 2;
or its tautomers, salts or solvates thereof.
10. A compound according to any of claims 1, 2 and 4 to 9, wherein R5 is hydrogen.
11. A compound according to any of claims 1, 2 and 4 to 9, wherein R5 is -OH.
12. A compound according to any of claims 1, 2 and 4 to 11, wherein X is O.
13. A compound according to claim 3 of formula (Ib’) 
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wherein Ra, R11, , Z, Pr and W are defined as in claim 3; 
or its tautomers, salts or solvates thereof.
14. A compound according to any of the previous claims, wherein W is aralkyl.
15. A compound according to claim 14, wherein W is -CRcRd-aryl, wherein Rc and Rd are each independently selected
from H, OH, OPr, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsub-
stituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubsti-
tuted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino and halogen.
16. A compound according to claim 15, wherein Rc and Rd are different.
17. A compound according to any of claims 15 and 16, wherein W is -CRcH-aryl, wherein Rc is selected from the group
consisting of OH, OPr, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino and halogen.
18. A compound according to claim 15, wherein Rc and Rd are both hydrogen.
19. A compound according to any of claims 1 to 3, wherein R1 is selected from the group consisting of-CH2-OC(=O)
alkyl and -CH2-OC(=O) Aryl.
20. A compound according to any of the previous claim, wherein Ra and Rb are different.
21. A compound according to any of claims 1 to 19, wherein Ra and Rb are both hydrogen.
22. Method for the synthesis of a compound of formula (I) which comprises one of the following procedures: 
(i) cyclation between the R2 group and the cyano group of a compound of formula (II) 
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wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in claim 1;
R5 is selected from the group consisting of hydrogen, -OH and -OPr; and
R2 is -OH or -OPr, Pr being a hydroxyl protecting group; wherein the cyano group and R2 are in relative
cis positions;
or its tautomers, salts or solvates thereof;
(ii) reacting a compound of formula (III)
wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in claim 1; and
R2 is -OH or -OPr, Pr being a hydroxyl protecting group;
or its tautomers, salts or solvates thereof;
in the presence of -CN; and, if necessary, epimerizing the C5 carbon atom of the compound of formula (II)
obtained;
(iii) dihydroxylating the double bond between C7 and C10 of a compound of formula (IV) 
wherein
R3, R5, R9, R10, Ra, Rb and W are as defined in claim 1; and
R5 is selected from the group consisting of hydrogen, -OH and -OPr;
or its tautomers, salts or solvates thereof;
(iv) hydrogenate a compound of formula (V) 
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wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in claim 1; and
R2 is -OH or -OPr;
or its tautomers, salts or solvates thereof; or
(v) diol protection of hydroxyl groups on C5 and C7 of a compound of formula (II) 
wherein
R1, R3, R9, R10, Ra, Rb and W are as defined in claim 1; and
R2 and R5 are both independently a -OH group in cis relative positions;
or its tautomers, salts or solvates thereof.
23. The method according to claim 22, wherein the compound of formula (III) reacts in the presence of TMSCN or Et2AlCN.
24. The method of any of claims 22 and 23 which comprises
a) reacting a compound of formula (VIII)
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wherein R2, R9, R10, R11, Ra, Rb and W are as defined in claim 1, or tautomers, salts or solvates thereof;
in the presence of -CN, to obtain a compound of formula (VII)
wherein R2, R9, R10, R11, Ra, Rb and W are as defined in claim 1, or tautomers, salts or solvates thereof;
b) oxidizing said compound of formula (VII); and
c) reacting the resulting compound of formula (III) in the presence of -CN; and, if necessary, epimerizing the
C5 carbon atom of the compound of formula (II)obtained.
25. The method of claim 24, wherein -CN source in steps a) and c) has the same formula.
26. Use of a compound of formula (I) as intermediate in the synthesis of TTX and analogues thereof.
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